<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5585007 - Plasma concentrate and tissue sealant methods and apparatuses for making ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant"><meta name="DC.contributor" content="Richard D. Antanavich" scheme="inventor"><meta name="DC.contributor" content="Randel Dorian" scheme="inventor"><meta name="DC.contributor" content="Plasmaseal Corporation" scheme="assignee"><meta name="DC.date" content="1994-12-7" scheme="dateSubmitted"><meta name="DC.description" content="An inexpensive device with a disposable cartridge for preparing tissue sealant is disclosed. The device is particularly applicable to star preparation of autologous tissue sealant. A method of sealing tissue in which the tissue sealant is applied immediately after mixing platelet-rich plasma concentrate (from the device) with a solution of calcium and thrombin is also disclosed. Preparation in the operating room of 5 cc sealant from 50 cc patient blood requires less than 15 minutes and only one simple operator step. There is no risk of tracking error because processing can be done in the operating room. Chemicals added may be limited to anticoagulant (e.g., citrate) and calcium chloride. The disposable cartridge may fit in the palm of the hand and is hermetically sealed to eliminate possible exposure to patient blood and ensure sterility. Adhesive and tensile strengths are comparable or superior to pooled blood fibrin sealants made with precipitation methods. Antifibrinolytic agents (such as aprotinin) are not necessary because the tissue sealant contains high concentrations of natural inhibitors of fibrinolysis from the patient&#39;s blood. The tissue sealant also contains patient platelets and additional factors not present in available fibrin sealants that promote wound healing."><meta name="DC.date" content="1996-12-17" scheme="issued"><meta name="DC.relation" content="BR:9103724" scheme="references"><meta name="DC.relation" content="CN:1074709:A" scheme="references"><meta name="DC.relation" content="DE:1443359:A1" scheme="references"><meta name="DC.relation" content="DE:4202667" scheme="references"><meta name="DC.relation" content="DE:56103" scheme="references"><meta name="DC.relation" content="EP:0090997:A2" scheme="references"><meta name="DC.relation" content="EP:0102773:A2" scheme="references"><meta name="DC.relation" content="EP:0109374:A1" scheme="references"><meta name="DC.relation" content="EP:0253198" scheme="references"><meta name="DC.relation" content="EP:0534178:A2" scheme="references"><meta name="DC.relation" content="EP:0592242:A1" scheme="references"><meta name="DC.relation" content="GB:854715" scheme="references"><meta name="DC.relation" content="US:2553004" scheme="references"><meta name="DC.relation" content="US:3453364" scheme="references"><meta name="DC.relation" content="US:3972812" scheme="references"><meta name="DC.relation" content="US:4059108" scheme="references"><meta name="DC.relation" content="US:4204537" scheme="references"><meta name="DC.relation" content="US:4225580" scheme="references"><meta name="DC.relation" content="US:4294707" scheme="references"><meta name="DC.relation" content="US:4298598" scheme="references"><meta name="DC.relation" content="US:4300717" scheme="references"><meta name="DC.relation" content="US:4303193" scheme="references"><meta name="DC.relation" content="US:4362567" scheme="references"><meta name="DC.relation" content="US:4377572" scheme="references"><meta name="DC.relation" content="US:4427650" scheme="references"><meta name="DC.relation" content="US:4427651" scheme="references"><meta name="DC.relation" content="US:4442655" scheme="references"><meta name="DC.relation" content="US:4453939" scheme="references"><meta name="DC.relation" content="US:4537767" scheme="references"><meta name="DC.relation" content="US:4627879" scheme="references"><meta name="DC.relation" content="US:4631055" scheme="references"><meta name="DC.relation" content="US:4632761" scheme="references"><meta name="DC.relation" content="US:4639316" scheme="references"><meta name="DC.relation" content="US:4650678" scheme="references"><meta name="DC.relation" content="US:4655211" scheme="references"><meta name="DC.relation" content="US:4672969" scheme="references"><meta name="DC.relation" content="US:4714457" scheme="references"><meta name="DC.relation" content="US:4735616" scheme="references"><meta name="DC.relation" content="US:4735726" scheme="references"><meta name="DC.relation" content="US:4755301" scheme="references"><meta name="DC.relation" content="US:4770779" scheme="references"><meta name="DC.relation" content="US:4818291" scheme="references"><meta name="DC.relation" content="US:4832851" scheme="references"><meta name="DC.relation" content="US:4874368" scheme="references"><meta name="DC.relation" content="US:4879031" scheme="references"><meta name="DC.relation" content="US:4902281" scheme="references"><meta name="DC.relation" content="US:4928603" scheme="references"><meta name="DC.relation" content="US:4943273" scheme="references"><meta name="DC.relation" content="US:4983157" scheme="references"><meta name="DC.relation" content="US:4983158" scheme="references"><meta name="DC.relation" content="US:4985153" scheme="references"><meta name="DC.relation" content="US:5000970" scheme="references"><meta name="DC.relation" content="US:5002571" scheme="references"><meta name="DC.relation" content="US:5030215" scheme="references"><meta name="DC.relation" content="US:5045048" scheme="references"><meta name="DC.relation" content="US:5071570" scheme="references"><meta name="DC.relation" content="US:5100564" scheme="references"><meta name="DC.relation" content="US:5112484" scheme="references"><meta name="DC.relation" content="US:5137832" scheme="references"><meta name="DC.relation" content="US:5141645" scheme="references"><meta name="DC.relation" content="US:5152905" scheme="references"><meta name="DC.relation" content="US:5156613" scheme="references"><meta name="DC.relation" content="US:5173295" scheme="references"><meta name="DC.relation" content="US:5185001" scheme="references"><meta name="DC.relation" content="US:5190057" scheme="references"><meta name="DC.relation" content="US:5190759" scheme="references"><meta name="DC.relation" content="US:5204537" scheme="references"><meta name="DC.relation" content="US:5206023" scheme="references"><meta name="DC.relation" content="US:5217426" scheme="references"><meta name="DC.relation" content="US:5217627" scheme="references"><meta name="DC.relation" content="US:5219328" scheme="references"><meta name="DC.relation" content="US:5226877" scheme="references"><meta name="DC.relation" content="US:5258126" scheme="references"><meta name="DC.relation" content="US:5260420" scheme="references"><meta name="DC.relation" content="US:5279825" scheme="references"><meta name="DC.relation" content="US:5281342" scheme="references"><meta name="DC.relation" content="US:5290552" scheme="references"><meta name="DC.relation" content="US:5290918" scheme="references"><meta name="DC.relation" content="US:5298171" scheme="references"><meta name="DC.relation" content="US:5304372" scheme="references"><meta name="DC.relation" content="US:5316674" scheme="references"><meta name="DC.relation" content="US:5321126" scheme="references"><meta name="DC.relation" content="US:5322620" scheme="references"><meta name="DC.relation" content="US:5330974" scheme="references"><meta name="DC.relation" content="US:5370802" scheme="references"><meta name="DC.relation" content="US:5376263" scheme="references"><meta name="DC.relation" content="US:5395923" scheme="references"><meta name="DC.relation" content="US:5403272" scheme="references"><meta name="DC.relation" content="US:5405607" scheme="references"><meta name="DC.relation" content="US:5411885" scheme="references"><meta name="DC.relation" content="US:5417650" scheme="references"><meta name="DC.relation" content="US:5420250" scheme="references"><meta name="DC.relation" content="US:5443481" scheme="references"><meta name="DC.relation" content="US:5456693" scheme="references"><meta name="DC.relation" content="WO:1988002259:A1" scheme="references"><meta name="DC.relation" content="WO:1990010031:A1" scheme="references"><meta name="DC.relation" content="WO:1992022312:A1" scheme="references"><meta name="DC.relation" content="WO:1993005067:A1" scheme="references"><meta name="citation_reference" content="Anesthesiology, vol. 81, No. 4, pp. 1074 1077, Oct. 1994, Hiromasa Mitsuhata, MD, et al., An Anaphylactic Reaction to Topical Fibrin Glue ."><meta name="citation_reference" content="Anesthesiology, vol. 81, No. 4, pp. 1074-1077, Oct. 1994, Hiromasa Mitsuhata, MD, et al., &quot;An Anaphylactic Reaction to Topical Fibrin Glue&quot;."><meta name="citation_reference" content="Ann Thorac Surg, vol. 53, pp. 530 531, 1992, Mehmet C. Oz, MD, et al., Autologous Fibrin GLue From Intraoperatively Collected Platelet Rich Plasma ."><meta name="citation_reference" content="Ann Thorac Surg, vol. 53, pp. 530-531, 1992, Mehmet C. Oz, MD, et al., &quot;Autologous Fibrin GLue From Intraoperatively Collected Platelet-Rich Plasma&quot;."><meta name="citation_reference" content="Ann Thorac Surg, vol. 56, pp. 387 389, 1993, Robert L. Quigley, MD. et al., Intraoperative Procurement of Autologous Fibrin Glue ."><meta name="citation_reference" content="Ann Thorac Surg, vol. 56, pp. 387-389, 1993, Robert L. Quigley, MD. et al., &quot;Intraoperative Procurement of Autologous Fibrin Glue&quot;."><meta name="citation_reference" content="Biopolymers, vol. 27, pp. 763 774, 1988, Gerald Marx; Mechanism of Fibrin Coagulation Based on Selective, Cation Driven, Protofibril Association ."><meta name="citation_reference" content="Biopolymers, vol. 27, pp. 763-774, 1988, Gerald Marx; &quot;Mechanism of Fibrin Coagulation Based on Selective, Cation-Driven, Protofibril Association&quot;."><meta name="citation_reference" content="Drug Intelligence and Clinical Pharmacy, vol. 22, pp. 946 952, Dec. 1988, Dennis F. Thompson, et al., Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects As A Topical Hemostat ."><meta name="citation_reference" content="Drug Intelligence and Clinical Pharmacy, vol. 22, pp. 946-952, Dec. 1988, Dennis F. Thompson, et al., &quot;Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects As A Topical Hemostat&quot;."><meta name="citation_reference" content="Journal of Biomaterials Applications, vol. 7, pp. 309 353, Apr. 1993, David H. Sierra, Fibrin Sealant Adhesive Systems: A Review of Their Chemistry, Material Properties and Clinical Applications ."><meta name="citation_reference" content="Journal of Biomaterials Applications, vol. 7, pp. 309-353, Apr. 1993, David H. Sierra, &quot;Fibrin Sealant Adhesive Systems: A Review of Their Chemistry, Material Properties and Clinical Applications&quot;."><meta name="citation_reference" content="Journal of Oral Maxillofacial Surgery, vol. 43, pp. 605 611, 1985, Helene Matras, MD, Fibrin Seal: The State of The Art ."><meta name="citation_reference" content="Journal of Oral Maxillofacial Surgery, vol. 43, pp. 605-611, 1985, Helene Matras, MD, &quot;Fibrin Seal: The State of The Art&quot;."><meta name="citation_reference" content="Laryngoscope, vol. 95, pp. 1074 1076, Sep. 1985, Karl H. Siedentop, MD, et al., Autologous Fibrin Tissue Adhesive ."><meta name="citation_reference" content="Laryngoscope, vol. 95, pp. 1074-1076, Sep. 1985, Karl H. Siedentop, MD, et al., &quot;Autologous Fibrin Tissue Adhesive&quot;."><meta name="citation_reference" content="Laryngoscope, vol. 96, pp. 1062 1064, Oct. 1986, Karl H. Siedentop, MD, et al., Extended Experimental and Preliminary Surgical Findings with Autologous Fibrin Tissue Adhesive Made From Patient s Own Blood ."><meta name="citation_reference" content="Laryngoscope, vol. 96, pp. 1062-1064, Oct. 1986, Karl H. Siedentop, MD, et al., &quot;Extended Experimental and Preliminary Surgical Findings with Autologous Fibrin Tissue Adhesive Made From Patient&#39;s Own Blood&quot;."><meta name="citation_reference" content="Laryngoscope, vol. 99, pp. 974 976, Sep. 1989, Kyosti Laitakari, MD, et al., Autologous and Homologous Fibrinogen Sealants: Adhesive Strength ."><meta name="citation_reference" content="Laryngoscope, vol. 99, pp. 974-976, Sep. 1989, Kyosti Laitakari, MD, et al., &quot;Autologous and Homologous Fibrinogen Sealants: Adhesive Strength&quot;."><meta name="citation_reference" content="Otolaryngologic Clinics of North America, vol. 27, No. 1, pp. 203 209, Feb. 1994, Dean M. Toriumi, MD, et al., Surgical Tissue Adhesives in Otolaryngology Head and Neck Surgery ."><meta name="citation_reference" content="Otolaryngologic Clinics of North America, vol. 27, No. 1, pp. 203-209, Feb. 1994, Dean M. Toriumi, MD, et al., &quot;Surgical Tissue Adhesives in Otolaryngology-Head and Neck Surgery&quot;."><meta name="citation_reference" content="The American Journal of Surgery, vol. 168, pp. 120 122, Aug. 1994, Roy L. Tawes, Jr. MD, et al., Autologous Fibrin Glue: The Last Step in Operative Hemostasis ."><meta name="citation_reference" content="The American Journal of Surgery, vol. 168, pp. 120-122, Aug. 1994, Roy L. Tawes, Jr. MD, et al., &quot;Autologous Fibrin Glue: The Last Step in Operative Hemostasis&quot;."><meta name="citation_reference" content="The American Surgeon, vol. 55, pp. 166 168, Mar. 1989, William D. Spotnitz, MD, et al., Successful Use of Fibrin Glue During 2 Years of Surgery At A University Medical Center ."><meta name="citation_reference" content="The American Surgeon, vol. 55, pp. 166-168, Mar. 1989, William D. Spotnitz, MD, et al., &quot;Successful Use of Fibrin Glue During 2 Years of Surgery At A University Medical Center&quot;."><meta name="citation_reference" content="Transfusion, vol. 30, No. 8, pp. 741 747, 1990, J. W. Gibble, et al., Fibrin Glue: The Perfect Operative Sealant ."><meta name="citation_reference" content="Transfusion, vol. 30, No. 8, pp. 741-747, 1990, J. W. Gibble, et al., &quot;Fibrin Glue: The Perfect Operative Sealant?&quot;."><meta name="citation_patent_number" content="US:5585007"><meta name="citation_patent_application_number" content="US:08/351,010"><link rel="canonical" href="http://www.google.com/patents/US5585007"/><meta property="og:url" content="http://www.google.com/patents/US5585007"/><meta name="title" content="Patent US5585007 - Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant"/><meta name="description" content="An inexpensive device with a disposable cartridge for preparing tissue sealant is disclosed. The device is particularly applicable to star preparation of autologous tissue sealant. A method of sealing tissue in which the tissue sealant is applied immediately after mixing platelet-rich plasma concentrate (from the device) with a solution of calcium and thrombin is also disclosed. Preparation in the operating room of 5 cc sealant from 50 cc patient blood requires less than 15 minutes and only one simple operator step. There is no risk of tracking error because processing can be done in the operating room. Chemicals added may be limited to anticoagulant (e.g., citrate) and calcium chloride. The disposable cartridge may fit in the palm of the hand and is hermetically sealed to eliminate possible exposure to patient blood and ensure sterility. Adhesive and tensile strengths are comparable or superior to pooled blood fibrin sealants made with precipitation methods. Antifibrinolytic agents (such as aprotinin) are not necessary because the tissue sealant contains high concentrations of natural inhibitors of fibrinolysis from the patient&#39;s blood. The tissue sealant also contains patient platelets and additional factors not present in available fibrin sealants that promote wound healing."/><meta property="og:title" content="Patent US5585007 - Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("BE3sU6NmwqXIBLGxgbgG"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("CAN"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("BE3sU6NmwqXIBLGxgbgG"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("CAN"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5585007?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5585007"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=kfFABAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5585007&amp;usg=AFQjCNF8YKyOD_6m1St9Fv0IjpEF-rrvWQ" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5585007.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5585007.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5585007" style="display:none"><span itemprop="description">An inexpensive device with a disposable cartridge for preparing tissue sealant is disclosed. The device is particularly applicable to star preparation of autologous tissue sealant. A method of sealing tissue in which the tissue sealant is applied immediately after mixing platelet-rich plasma concentrate...</span><span itemprop="url">http://www.google.com/patents/US5585007?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5585007 - Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5585007 - Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant" title="Patent US5585007 - Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5585007 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/351,010</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Dec 17, 1996</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Dec 7, 1994</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Dec 7, 1994</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/DE69535846D1">DE69535846D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0743957A1">EP0743957A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0743957A4">EP0743957A4</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0743957B1">EP0743957B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5788662">US5788662</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6063297">US6063297</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6214338">US6214338</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1996017871A1">WO1996017871A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08351010, </span><span class="patent-bibdata-value">351010, </span><span class="patent-bibdata-value">US 5585007 A, </span><span class="patent-bibdata-value">US 5585007A, </span><span class="patent-bibdata-value">US-A-5585007, </span><span class="patent-bibdata-value">US5585007 A, </span><span class="patent-bibdata-value">US5585007A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Richard+D.+Antanavich%22">Richard D. Antanavich</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Randel+Dorian%22">Randel Dorian</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Plasmaseal+Corporation%22">Plasmaseal Corporation</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5585007.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5585007.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5585007.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (98),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (28),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (147),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (31),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (14)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5585007&usg=AFQjCNER_2r8soIsp6BMims-tCUuxPHGVQ">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5585007&usg=AFQjCNE6gfmxg3Ejv8_sdUJ5IoY19PEqjA">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5585007A%26KC%3DA%26FT%3DD&usg=AFQjCNEBKEQLPDeVDIcys080pYAlIGne4g">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT54110341" lang="EN" load-source="patent-office">Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant</invention-title></span><br><span class="patent-number">US 5585007 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA37595334" lang="EN" load-source="patent-office"> <div class="abstract">An inexpensive device with a disposable cartridge for preparing tissue sealant is disclosed. The device is particularly applicable to star preparation of autologous tissue sealant. A method of sealing tissue in which the tissue sealant is applied immediately after mixing platelet-rich plasma concentrate (from the device) with a solution of calcium and thrombin is also disclosed. Preparation in the operating room of 5 cc sealant from 50 cc patient blood requires less than 15 minutes and only one simple operator step. There is no risk of tracking error because processing can be done in the operating room. Chemicals added may be limited to anticoagulant (e.g., citrate) and calcium chloride. The disposable cartridge may fit in the palm of the hand and is hermetically sealed to eliminate possible exposure to patient blood and ensure sterility. Adhesive and tensile strengths are comparable or superior to pooled blood fibrin sealants made with precipitation methods. Antifibrinolytic agents (such as aprotinin) are not necessary because the tissue sealant contains high concentrations of natural inhibitors of fibrinolysis from the patient's blood. The tissue sealant also contains patient platelets and additional factors not present in available fibrin sealants that promote wound healing.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(4)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5585007-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5585007-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5585007-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5585007-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5585007-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5585007-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5585007-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5585007-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(45)</span></span></div><div class="patent-text"><div mxw-id="PCLM5041969" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed as new and is desired to be secured by letters patent of the United States is:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A method of making concentrated plasma for use as a tissue sealant or adhesive, comprising the steps of:<div class="claim-text">(a) separating plasma from whole blood;</div> <div class="claim-text">(b) removing water from said plasma by contacting said plasma with a concentrator which does not significantly denature fibrinogen to provide said concentrated plasma; and</div> <div class="claim-text">(c) separating said concentrated plasma from said concentrator.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. The method of claim 1, wherein said separating step (a) comprises centrifugally contacting said whole blood with a separator which bars passage of red blood cells and white blood cells in the absence of an applied centrifugal force, and applying a centrifugal force effective to pass red blood cells and white blood cells in said whole blood through said separator.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. The method of claim 2, wherein said separator is a mat, foam or porous plastic annulus.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. The method of claim 1, wherein said separating step (a) comprises centrifugally settling said whole blood into a chamber shaped and positioned such that gravity does not permit drainage of said red blood cells and said white blood cells in the absence of an applied centrifugal force.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. The method of claim 1, wherein each of said whole blood and said plasma contains (i) platelets, (ii) high molecular weight compounds or (iii) both platelets and high molecular weight compounds.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. A platelet-rich plasma concentrate, prepared by the process of claim 5.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. The method of claim 1, wherein said concentrator comprises a material selected from the group consisting of a dextranomer, dextramine, polyacrylamide, silica gel, a zeolite, cross-linked agarose, starch and alginate gel, either in free bead form or attached to a surface.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. The method of claim 7, wherein said material is attached to a matrix, and said matrix comprises a mat, a foam or a disc.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. The method of claim 1, wherein said blood contains an amount of an added coagulation inhibitor which is effective to inhibit coagulation of said blood.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. The method of claim 1, conducted in a sealed cartridge having an inlet, a first chamber containing a first separator for separating said plasma from said whole blood, a second chamber containing said concentrator and a second separator for separating said concentrated plasma from said concentrator, and an outlet for withdrawing said concentrated plasma.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" class="claim">
      <div class="claim-text">11. The method of claim 1, further comprising, after said separating step (c), repeating said contacting step (b) and said separating step (c).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" class="claim">
      <div class="claim-text">12. A plasma concentrate, prepared by the process of claim 1.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" class="claim">
      <div class="claim-text">13. The plasma concentrate of claim 12, wherein said plasma concentrate is autologous.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="14" class="claim">
      <div class="claim-text">14. A tissue sealant, comprising the plasma concentrate of claim 12 and an activator.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="15" class="claim">
      <div class="claim-text">15. The tissue sealant of claim 14, wherein said activator is a mixture of thrombin and calcium in amounts sufficient to permit gelation of said platelet-rich plasma concentrate.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="16" class="claim">
      <div class="claim-text">16. The tissue sealant of claim 14, wherein said activator is autologous thrombin and platelets.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="17" class="claim">
      <div class="claim-text">17. A method of sealing tissue, comprising the steps of:<div class="claim-text">(a) preparing a plasma concentrate according to the process of claim 1,</div> <div class="claim-text">(b) activating said plasma concentrate to provide an activated plasma concentrate, and</div> <div class="claim-text">(c) applying said activated plasma concentrate to tissue in need of sealing.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="18" class="claim">
      <div class="claim-text">18. The method of claim 17, wherein said plasma concentrate is obtained from blood drawn from a patient, and said tissue in need of sealing is in or on said patient.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="19" class="claim">
      <div class="claim-text">19. The method of claim 17, wherein said activating comprises contacting said plasma concentrate with a mixture of thrombin and calcium in amounts sufficient to gel said activated plasma concentrate.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="20" class="claim">
      <div class="claim-text">20. A method of sealing tissue, comprising the steps of:<div class="claim-text">(a) preparing a plasma concentrate according to the process of claim 1, said plasma concentrate containing prothrombin, platelets or both prothrombin and platelets,</div> <div class="claim-text">(b) activating said prothrombin, said platelets or both said prothrombin and said platelets to provide an activated plasma concentrate, and</div> <div class="claim-text">(c) applying said activated plasma concentrate to tissue in need of sealing.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="21" class="claim">
      <div class="claim-text">21. The method of claim 20, wherein said activating comprises irradiating said platelets with ultrasound sufficiently to result in gelation of said activated plasma concentrate.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="22" class="claim">
      <div class="claim-text">22. The method of claim 20, wherein said activating comprises heating said plasma concentrate sufficiently to result in gelation of said activated plasma concentrate.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="23" class="claim">
      <div class="claim-text">23. The apparatus of claim 21, wherein said concentrator has a molecular weight cutoff of from 2 to 100 kDa.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="24" class="claim">
      <div class="claim-text">24. The apparatus of claim 21, wherein said concentrator is selected from the group consisting of a dextranomer, dextramine, polyacrylamide, silica gel, a zeolite, cross-linked agarose, starch and alginate gel, either in free bead form or attached to a surface.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="25" class="claim">
      <div class="claim-text">25. The apparatus of claim 21, wherein said concentrator is embedded in or attached to a surface.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="26" class="claim">
      <div class="claim-text">26. The apparatus of claim 25, wherein said matrix comprises a plurality of discs.</div>
    </div>
    </div> <div class="claim"> <div num="27" class="claim">
      <div class="claim-text">27. A plasma concentrate comprising platelets, from 5 to 400 mg/ml of fibrinogen, from 0.5 to 35 mg/ml of fibronectin, and a physiologically acceptable carrier comprising water and physiologically acceptable inorganic and organic ions in a physiological acceptable concentration, wherein the fibrinogen in the concentrate is not significantly denatured.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="28" class="claim">
      <div class="claim-text">28. The plasma concentrate of claim 27, prepared from whole blood, wherein said platelets are present in said plasma concentrate in a concentration of at least one-and-one-half times the concentration of said platelets in unconcentrated plasma from said whole blood.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="29" class="claim">
      <div class="claim-text">29. The plasma concentrate of claim 27, further containing a compound selected from the group consisting of an antibiotic, a collagen fleece, collagenase, hyaluronic acid, a wound-healing factor, zinc ions in an amount effective to decrease coagulation time of said plasma, and a biologically acceptable dye.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="30" class="claim">
      <div class="claim-text">30. The plasma concentrate of claim 29, further containing disulphine blue in an amount sufficient to visibly detect said plasma concentrate during its application to tissue.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="31" class="claim">
      <div class="claim-text">31. The plasma concentrate of claim 27, further comprising a pharmaceutically active compound.</div>
    </div>
    </div> <div class="claim"> <div num="32" class="claim">
      <div class="claim-text">32. A method of making concentrated plasma for use as a tissue sealant or adhesive, comprising the steps of:<div class="claim-text">(a) separating plasma from whole blood; and</div> <div class="claim-text">(b) removing water from said plasma with a concentrator which does not significantly denature fibrinogen to provide said concentrated plasma.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="33" class="claim">
      <div class="claim-text">33. A method of claim 32 wherein the concentrator is a water-absorbent.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="34" class="claim">
      <div class="claim-text">34. A method of claim 33 wherein the concentrator is a material selected from the group consisting of a dextranomer dextramine, polyacrylamide, silica gel, a zeolite, cross-linked agarose, starch and alginate gel.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="35" class="claim">
      <div class="claim-text">35. A method of claims 34 wherein the concentrator is a free bead form or attached to a surface.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="36" class="claim">
      <div class="claim-text">36. A method of claim 32 wherein the concentrator includes a membrane.</div>
    </div>
    </div> <div class="claim"> <div num="37" class="claim">
      <div class="claim-text">37. An apparatus with a disposable cartridge for concentrating plasma for use as a tissue sealant or adhesive, comprising a centrifuge separator means for separating plasma from whole blood; and concentrator means in fluid communication with said centrifuge separator means for removing water from said plasma without significantly denaturing fibrinogen, to provide concentrated plasma.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="38" class="claim">
      <div class="claim-text">38. An apparatus of claim 37 comprising a first chamber containing the centrifuge separator for separating plasma from whole blood; and a second chamber in fluid communication with said first chamber, the second chamber including a concentrator means for concentrating said plasma by removing water from said plasma without significantly denaturing fibrinogen and a second separator for separating concentrated plasma from said concentrator.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="39" class="claim">
      <div class="claim-text">39. An apparatus of claim 38 wherein the concentrator means comprises a material selected from the group consisting of a dextranomer, dextramine, polyacrylamide, silica gel, a zeolite, cross-linked agarose, starch and alginate gel.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="40" class="claim">
      <div class="claim-text">40. An apparatus of claim 39 wherein the concentrator means is a free bead form or attached to a surface.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="41" class="claim">
      <div class="claim-text">41. An apparatus of claim 38 wherein the concentrator means includes a membrane.</div>
    </div>
    </div> <div class="claim"> <div num="42" class="claim">
      <div class="claim-text">42. A plasma concentrate containing fibrinogen for use as a tissue sealant or adhesive, the fibrinogen in said concentrate not being significantly denatured.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="43" class="claim">
      <div class="claim-text">43. A plasma concentrate of claim 42 containing from 5 to 400 mg/ml of fibrinogen.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="44" class="claim">
      <div class="claim-text">44. A plasma concentrate made by the process of claim 38.</div>
    </div>
    </div> <div class="claim"> <div num="45" class="claim">
      <div class="claim-text">45. An apparatus with a disposable cartridge for concentrating plasma for use as a tissue sealant or adhesive, comprising:<div class="claim-text">an inlet,</div> <div class="claim-text">a first chamber in fluid communication with said inlet, the first chamber containing a centrifuge separator for separating plasma from whole blood,</div> <div class="claim-text">a second chamber in fluid communication with said first chamber, the second chamber containing a concentrator for concentrating said plasma by removing water from said plasma without significantly denaturing fibrinogen and a second separator for separating concentrated plasma from said concentrator, and</div> <div class="claim-text">an outlet for withdrawing said concentrated plasma.</div> </div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES66859475" lang="EN" load-source="patent-office" class="description">
    <heading>BACKGROUND OF THE INVENTION</heading> <p>1. Field of the Invention</p>
    <p>The present invention concerns compositions, methods and apparatuses for making concentrated plasma and tissue sealant, for sealing tissue, for rapid separation of higher molecular weight components in mixtures, for rapid separation of blood plasma and for rapid separation of particulate components in mixtures. The present invention is particularly applicable to preparation and use of autologous tissue sealant.</p>
    <p>2. Discussion of the Background</p>
    <heading>Fibrin Glues and Sealants</heading> <p>Various substances have been tried to meet the need for a suitable tissue adhesive for use in surgical procedures. Completely synthetic materials such as cyanoacrylate have been tried and been found wanting. Natural fibrin glues and sealants made from blood components were recognized early in the development of this technology. Surgical "fibrin sealants" (sometimes called "fibrin glues") made up of human fibrinogen activated by bovine thrombin are used extensively in Europe. Such fibrin sealants have been shown to be superior to synthetic adhesives or traditional surgery in many situations. In addition they reduce the need for blood transfusions. Academic and surgical opinion on fibrin sealants is very favorable. A recent review says:</p>
    <p>Fibrin sealants are the most successful tissue adhesives to date. They have many advantages over adhesive technologies such as cyanoacrylates and marine adhesives in terms of biocompatibility, biodegradation and hemostasis. There are several commercial products in Europe but none in the United States due to the current regulatory stance against pooled plasma blood products (Sierra, 1993; vide infra).</p>
    <p>In current practice, fibrin sealant is made by isolating a concentrate of human fibrinogen, fibronectin and factor XIII, usually by cryoprecipitation, and combining it immediately before use with bovine (or sometimes human) thrombin. The thrombin converts the fibrinogen to fibrin which rapidly gels to form a transient hemostatic plug, which is then stabilized by factor XIII. Fibronectin provides adhesion for cells repopulating the clot and tissue. The most common method of application of fibrin sealant is mixing of concentrated fibrinogen from pooled human blood with bovine thrombin and calcium immediately before use.</p>
    <p>Fibrin sealant is not available in the U.S. commercially, but is in Europe (TISSEEL, TISSUCOL/Immuno; BERIPLAST/Behring). Many papers have been published on its use.</p>
    <p>Use of fibrin sealant in the United States is limited to preparation within the clinic outside FDA control. The reasons for FDA reluctance to approve these products in the United States are:</p>
    <p>virus transmission (e.g., HIV, hepatitis) from pooled human blood<sup>1</sup> and</p>
    <p>immunological reactions to bovine thrombin<sup>2</sup>, for example thrombin and factor V inhibitors or foreign body reactions<sup>3</sup>.</p>
    <p>These FDA concerns are so serious that the FDA has not approved any fibrin sealant product, despite strong interest from surgeons and very favorable comparative studies in the literature.</p>
    <p>These circumstances have led to much attention being given to methods to isolate an autologous counterpart of the fibrinogen containing component in the TISSUCOL system in a practical manner. These efforts are discussed in the reviews cited below. The following from a review by Thompson<sup>4</sup> shows that the value of star autologous fibrinogen is much anticipated:</p>
    <p>Fibrin glue is composed of two separate solutions of fibrinogen and thrombin. When mixed together, these agents mimic the last stages of the clotting cascade to form a fibrin clot. Fibrin glue is available in Europe but is not commercially available in the U.S.; therefore, investigators have extemporaneously compounded their own fibrin glue. Fibrinogen can be obtained from pooled, single-donor, and autologous blood donors and is usually isolated by the process of cryoprecipitation. . . . The safest preparations use the patient's own blood to prepare fibrin glue. . . . Use of. . . autologous blood results in minimal risk of disease transmission, but it requires anticipated use as in an elective procedure. The use of autologous blood usually is not possible in trauma or an emergency surgical procedure.</p>
    <p>Siedentop<sup>5</sup> describes a number of approaches to the precipitation of fibrinogen from plasma in the context of the proposed use of this material as the fibrinogen furnishing component of a fibrin glue. Four methods were suggested: precipitation with ethanol, use of unfractionated plasma, cryoprecipitation, and precipitation with ammonium sulfate. Epstein<sup>6</sup> suggests the use of a fibrinogen preparation from autologous plasma obtained using polyethylene glycol precipitation. A system for preparing autologous tissue adhesive using a relatively complex system based on ethanol precipitation has been described by Weis-Fogh<sup>7</sup>. Because none of these methods has yet produced a clearly superior autologous sealant, research in the past five years has continued on several approaches including plasma sealant<sup>8</sup>, ethanol precipitation<sup>9</sup> and rapid cryoprecipitation<sup>10</sup>. Prior patents are discussed in later sections, Autologous Precipitate Sealants and Autologous Plasma Sealants.</p>
    <p>None of these methods is readily adaptable for convenient use of an autologous plasma fraction as an adhesive which can be prepared quickly during the surgical procedure. All of the approaches suggested for preparation of the fibrinogen containing fraction for this purpose are too time-consuming and complex to be finished in a short enough time to be accomplished during the surgery. Also, in some procedures, such as cryoprecipitation, special equipment, such as refrigerated centrifuges, is required. While the prior art approach is to prepare the composition in advance, this immediately imposes the necessity for additional procedures for identification and retrieval of the samples matched with the patient, and the concomitant opportunity for error, besides the inconvenience to the patient, who must then arrange time for an additional medical appointment. And, of course, this practice is not possible when the surgery is conducted on an emergency basis.</p>
    <p>Several useful reviews on surgical glues generally and on fibrin glues particularly have been published (Sierra, D. H. "Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications." J Biomater Appl 7 (4 1993): 309-52; Wiseman, David M., David T. Rovee, and Oscar M. Alverez. "Wound Dressings: Design and Use." In Wound Healing: Biochemical &amp; Clinical Aspects, ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 562-580. 1st ed., Vol. Philadelphia: W. B. Saunders Company, 1992). A review of devices used by surgeons discusses fibrin glue in context of both hemostatic agents and adhesive agents (Edlich, Richard F., George T. Rodehearer, and John G. Thacker. "Surgical Devices in Wound Healing Management." In Wound Healing: Biochemical &amp; Clinical Aspects, ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 581-600. 1st ed., Vol. Philadelphia: W. B. Saunders Company, 1992). A review of the role of fibrin and fibrinogen in blood coagulation has also been published (Jackson, C. M. and Y. Nemerson. "Blood coagulation." Annu Rev Biochem 49 (811 1980): 765-811). Other reviews, in reverse chronological order, include:</p>
    <p>(1) Lerner, R. and N. S. Binur. "Current status of surgical adhesives." J Surg Res 48 (2 1990): 165-81.</p>
    <p>(2) Gibble, J. W. and P. M. Ness. "Fibrin glue: the perfect operative sealant?" Transfusion 30 (8 1990): 741-7.</p>
    <p>(3) Thompson, D. F., N. A. Letassy, and G. D. Thompson. "Fibrin glue: a review of its preparation, efficacy, and adverse effects as a topical hemostat." Drug Intell Clin Pharm 22 (12 1988): 946-52.</p>
    <heading>Biological Precipitate Sealants</heading> <p>The vast majority of prior methods for preparing blood derived glues or sealants use fibrinogen precipitated (usually cryoprecipitated) from pooled plasma, a method first published in 1972<sup>11</sup>. Most biological sealant patents are improvements on cryoprecipitation. Most go through a lyophilization step before application. A few touch on plasma, but none mentions a composition derived from concentrated plasma.</p>
    <p>A composition from cryoprecipitation method was patented by Immuno AG<sup>12</sup>. Since the basic method had been published previously, the composition claims were precisely descriptive:</p>
    <p>Exemplary Claim: 1. A lyophilized tissue adhesive of mammalian protein origin which comprises fibrinogen, albumin, factor XIII, cold-insoluble globulin and plasminogen-activator inhibitor or plasmin inhibitor wherein the fibrinogen is present in at least 33% by weight, the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen is at least 80; and fibrinogen and albumin are present in a ratio of 33 to 90:5 to 40.</p>
    <p>Several inventions have improved on early cryoprecipitation methods. A variation of cryoprecipitation is claimed to produce material superior for patients with blood coagulation disorders<sup>13</sup>. Stroetmann overcame problems by mixing fibrinogen, thrombin and protease inhibitor in lyophilized form for administration as a powder<sup>14</sup>. Behring found a way to improve solubility of (poorly soluble) cryoprecipitate<sup>15</sup>. French scientists have improved the traditional cryoprecipitation by using a double cold ethanol precipitation<sup>16</sup>. Epstein has a patent application for precipitation with polyethylene glycol (only the sister (device) patent has issued)<sup>17</sup>. Cryolife has crafted a patent with a broad exemplary claim<sup>18</sup> (quoted in note), but all the claims are limited by use of a precipitation step.</p>
    <p>Sierra's group has patented compositions with collagen added to fibrinogen. The notion is that collagen improves the mechanical properties of the sealant<sup>19</sup>. Related approaches are addition of hyaluronic acid to make the solution more viscous before gelation (patent application)<sup>20</sup> and addition of silk fibroin for mechanical strength<sup>21</sup>.</p>
    <p>A disclosed World patent application shows that Baxter is using fibrinogen affinity chromatography to get around the problems with precipitation<sup>22</sup>. A disclosed European patent application shows that Squibb scientists have developed a method eliminating the need for thrombin<sup>23</sup>. They use fibrin made by passing fibrinogen through a column with immobilized snake-venom; chaotropic agents prevent gelation. According to this work, "(f)ibrin I monomer is preferred because it can, in contrast to fibrinogen, readily be converted to fibrin polymer without the use of thrombin or factor XIII." From blood, the method yields 60-90% fibrin monomer. It is activated by calcium and a pH change.</p>
    <p>The majority of biological patents assume a precipitation step in the manufacture of the tissue sealant.</p>
    <heading>Autologous Preoipitate Sealants</heading> <p>As discussed above, it is widely recognized that autologous blood products are superior for safety and biocompatibility reasons alone. Columbia University has patented the use of autologous fibrin glue<sup>24</sup>, but the claims are restricted to cryoprecipitate. A European patent application makes similar claims<sup>25</sup>, but again the claims are restricted to cryoprecipitate.</p>
    <heading>Autologous Plasma Sealants</heading> <p>Alterbaum has patented using small quantities of patient plasma to make tissue glue<sup>26</sup>, but the plasma is not concentrated and the claims are restricted to use of flat pack centrifugation for isolation of the plasma.</p>
    <p>1. A method for use in the autologous preparation of fibrin glue wherein a patient's blood is separated in a centrifuge having cylindrical cups pivotally mounted to a rotor to obtain plasma and wherein the plasma is separated in the centrifuge to produce concentrated fibrinogen, comprising the steps of: (a) transferring the blood or plasma into a substantially flat packet; (b) fixing the packet containing the blood or plasma in a recess of a substantially cylindrical insert fixture assembly; (c) inserting said cylindrical-shaped insert fixture assembly in a cup of the centrifuge having a complementary cylindrical shape so that the insert fixture assembly is held snugly within said centrifuge cup; (d) centrifuging the blood or plasma contained within said packet fixed in said insert fixture assembly held in said centrifuge cup to separate the blood or plasma into components; and (e) forming fibrin glue from one of said separated components.</p>
    <p>Although no claim mentions or suggests concentrating the plasma, the patent which appears to be most similar to the present invention (Dennis Galanakis, SUNY Stony Brook) covers unconcentrated plasma glue<sup>27</sup> :</p>
    <p>1. A method of treating with autologous mammalian plasma fibrin to affect hemostasis, comprising the steps of: (a) obtaining a sample of blood from said animal; (b) substantially immediately separating the whole plasma from said blood obtained in step (a); and (c) contacting said whole plasma resulting from step (b) with thrombin in a physiologically acceptable solution at a rate and in a volume at the site of treatment to provide fibrin coagulation at said site.</p>
    <heading>Applicators</heading> <p>Application of fibrin glue requires mixing the two components under controlled conditions because gelation can be very rapid. The earliest applicator patents are assigned to Immuno AG. The principal claims revolve around different syringe diameters to limit dilution of the fibrinogen component by using a smaller volume of more highly concentrated thrombin<sup>28</sup> and the use of medical gas to keep the syringe applicator/mixer clear of gel<sup>29</sup>. Galanakis described an application in which the two liquids do not mix internally but are applied side-by-side from tubes that run in parallel all the way to the point of application.<sup>27</sup> Very similar claims were made previously by Micromedics<sup>30</sup>. Corus Medical has an aerosol device driven by pressurized gas<sup>31</sup>. The Cryolife approach is to prevent gelation in a single-component fibrin glue by pH inhibition of thrombin<sup>32</sup>. Gordon Epstein has patented the use of a third suction tip to dry the surface before application<sup>17</sup>.</p>
    <heading>Plasma Separators</heading> <p>Haemonetics' "bowl" technology allows separation of plasma continuously by a method which differs from the methods of the present invention disclosed below<sup>33</sup>. Several patents address isolation of platelets from blood using centrifuge sedimentation methods<sup>34</sup> or red cell barriers<sup>35</sup>, but none claims an approach similar to the ones described herein including sintered (porous) plastic or in which the cells pass through a barrier, leaving platelet-rich plasma behind.</p>
    <heading>Dextrans</heading> <p>Pharmacia has basic patents on dextranomers<sup>36</sup> and on their use in wound healing.<sup>37</sup> Interestingly, concentration of proteins (including fibrinogen) in the vicinity of the wound by differential absorption of water and electrolytes is identified as a benefit of the technology, but the claims are limited to methods in which the dextranomer beads are applied to the wound.</p>
    <heading>Other Patents of Interest</heading> <p>Fibrin sealants have been claimed as a component in a composition to repair cartilage<sup>38</sup>, to help in eye surgery<sup>39</sup> and with heat-melted collagen for "tissue welding<sup>40</sup>." Another approach has been to use fibrinogen/thrombin powder to coat a biodegradable fiber to stop puncture bleeding<sup>41</sup>, or in a collagen sponge or mat with powdered fibrin sealant<sup>42</sup>. Addition of collagenase to fibrin sealant to improve nerve healing has been patented by Wehling<sup>43</sup>. Pharmacia has patented the use of hyaluronic acid to prevent adhesions<sup>44</sup>.</p>
    <heading>Summary of Current Use of Fibrin Sealants in the United States</heading> <p>Although wounds heal naturally, medicine seeks to improve and speed the wound healing process. The body's blood clotting and tissue repair mechanisms are complex cascades progressing from blood proteins (e.g. fibrinogen) to specialized repair cells (fibroblasts). Sutures, surgical staples or surgical adhesives hold the damaged tissues together so that healing can progress. Surgical "fibrin sealants," sometimes called "fibrin glues," made up of human fibrinogen activated by bovine thrombin are used extensively in Europe. Such fibrin sealants have been shown to be superior to synthetic adhesives or traditional surgery in many situations. In addition they reduce the need for blood transfusions. Academic surgical opinion on fibrin sealants is very favorable (see the reviews cited above).</p>
    <p>In current practice, fibrin sealant is made by isolating a concentrate of human fibrinogen, fibronectin and factor XIII, usually by cryoprecipitation, and combining it immediately before use with bovine thrombin. The thrombin converts the fibrinogen to fibrin which then gels rapidly to form a transient hemostatic plug. The most common method of application of fibrin sealant is by mixing of concentrated fibrinogen from pooled human blood with bovine thrombin and calcium immediately before use.</p>
    <p>Fibrin sealant is not available in the U.S. commercially, but is in Europe. The FDA is reluctant to approve these products in the United States because of the potential for virus transmission (e.g., HIV, hepatitis) from pooled human blood and the potential for immunological reactions. These FDA concerns are so serious that the FDA has not approved any fibrin sealant product, despite strong interest from surgeons and very favorable comparative studies in the literature.</p>
    <p>1. Hennis, H. L., W. C. Stewart, and E. K. Jeter. "Infectious disease risks of fibrin glue [letter]." Ophthalmic Surg 23 (9 1992): 640.</p>
    <p>2. Berguer, R., R. L. Staerkei, E. E. Moore, F. A. Moore, W. B. Galloway, and M. B. Mockus. "Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports." J Trauma 31 (3 1991): 408-11.</p>
    <p>Berruyer, M., J. Amiral, P. Ffrench, J. Belleville, O. Bastien, J. Clerc, A. Kassir, S. Estanove, and M. Dechavanne. "Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors." J Thorac Cardiovasc Surg 105 (5 1993): 892-7.</p>
    <p>3. Sanal, M. "Does fibrin glue cause foreign body reactions? [letter]." Eur J Pediatr Surg 3 (3 1993): 190. Sanal, M., H. Dogruyol, A. Gurpinar, and O. Yerci. "Does fibrin glue cause foreign body reactions?" Eur J Pediatr Surg 2 (5 1992): 285-6.</p>
    <p>4. Thompson, D. F., Letassy, N. A., and Thompson, G. D., Fibrin glue: a review of its preparation, efficacy, and adverse effects as a topical hemostat. Drug Intell Clin Pharm, 1988. 22(12): p. 946-52.</p>
    <p>5. Siedentop, K. H., D. M. Harris, and B. Sanchez. "Autologous fibrin tissue adhesive." Laryngoscope 95 (9 Pt 1 1985): 1074-6.</p>
    <p>6. Epstein, G. H., R. A. Weisman, S. Zwillenberg, and A.D. Schreiber. "A new autologous fibrinogen-based adhesive for otologic surgery." Ann Otol Rhinol Laryngol 95 (1 Pt 1 1986): 40-5.</p>
    <p>7. Weis-Fogh, U.S. "Fibrinogen prepared from small blood samples for autologous use in a tissue adhesive system." Eur Surg Res 20 (5-6 1988): 381-9.</p>
    <p>8. Hartman, A. R., D. K. Galanakis, M. P. Honig, F. C. Seifert, and C. E. Anagnostopoulos. "Autologous whole plasma fibrin gel. Intraoperative procurement." Arch Surg 127 (3 1992): 357-9.</p>
    <p>9. Kjaergard, H. K., Fogh Us Weis, and J. J. Thiis. "Preparation of autologous fibrin glue from pericardial blood." Ann Thorac Surg 55 (2 1993): 543-4.</p>
    <p>Kjaergard, H. K., U.S. Weis-Fogh, H. Sorensen, J. Thiis, and I. Rygg. "A simple method of preparation of autologous fibrin glue by means of ethanol." Surg Gynecol Obstet 175 (1 1992): 72-3.</p>
    <p>10. Casali, B., F. Rodeghiero, A. Tosetto, B. Palmieri, R. Immovilli, C. Ghedini, and P. Rivasi. "Fibrin glue from single-donation autologous plasmapheresis." Transfusion 32 (7 1992): 641-3.</p>
    <p>Moretz, W, Jr., J Shea Jr., J. R. Emmett, and J Shea. "A simple autologous fibrinogen glue for otologic surgery." Otolaryngol Head Neck Surg 95 (1 1986): 122-4.</p>
    <p>11. Matras, Helene, H. P. Dinges, H. Lassmann, and B. Mamoli. "Zur nahtlosen interfaszikularen Nerventransplantation im Tierexperiment." Wein Med Woschtr 122 (37 1972): 517-523.</p>
    <p>First clinical results: Kuderma, H. and Helene Matras. "Die klinische Anwendung der Klebung yon Nervenanastomosen mit Gerinnungssubstanzen bei der Rekonstruction verletzter peripherer Nerven." Wein Klin Wochenschr 87 (15 1975): 495-501.</p>
    <p>12. Schwarz, O., Linnau, Y., Loblich, F., and Seelich, T., Tissue adhesive; freeze dried wound healing agent containing Fibrinogen, albumin, factor XIII, globulin, and plasminogen blocking Agent. U.S. Pat. No. 4,414,976 (1983); Schwarz, O., Linnau, Y., Loblich, F., and Seelich, T., Tissue adhesive; factor viii, proteins, fibrinogen, globulin, albumin and plasmin inhibitor. U.S. Pat. No. 4,377,572 (1982); Schwarz, O., Linnau, Y., Loblich, F., and Seelich, T., Tissue adhesive; fibrinogen, factor XIII, albumin, plasmin inhibitor. U.S. Pat. No. 4,362,567 (1982); Schwarz, O., Linnau, Y., Loblich, F., and Seelich, T., Tissue adhesive; blood proteins; surgery. U.S. Pat. No. 4,298,598 (1981); assigned to Immuno AG.</p>
    <p>13. Martinowitz, U. and Bal, F., Improved tissue glue prepared by using cryoprecipitate. EP (application) Patent 534,178 (1993) Assigned to Octapharma AG.</p>
    <p>14. Stroetmann, M., Enriched plasma derivative for advancement of wound closure and healing. U.S. Pat. No. 4,427,650 (1984); Stroetmann, M., Fibrinogen-containing dry preparation, manufacture and use thereof. U.S. Pat. No. 4,442,655 (1984); Stroetmann, M., Enriched plasma derivative for enhancement of wound closure and coverage. U.S. Pat. No. 4,427,651 (1984); assigned to Serapharm Michael Stroetmann DE.</p>
    <p>15. Fuhge, P., Heimberger, N., Stohr, H.-A., and Burk, W., Readily Dissolvable Lyophilized Fibrinogen Formulation. U.S. Pat. No. 4,650,678 (1987) Assigned to Behringwerke Aktiengesellschaft.</p>
    <p>16. Burnouf-Radosevich, M. and Burnouf, T., Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof. U.S. Pat. No. 5,260,420 (1993) Assigned to Centre Regional de Transfusion Sanguine de Lille.</p>
    <p>17. Epstein, G. H., Method and apparatus for preparing fibrinogen adhesive from whole blood. U.S. Pat. No. 5,226,877 (1993).</p>
    <p>18. Morse, B. S., Carpenter, J. F., Turner, A.D., and Cryolife, I., Preparation of fibrinogen/factor XIII precipitate. U.S. Pat. No. 5,030,215 (1991) Assigned to Cryolife. Claim 1: A system for collecting a blood coagulation factor comprising a first container means for receiving whole blood, said first container means having an upper end, a lower end, at least one inlet port, add at least one outlet port; first conduit means for conveying whole blood to said first container means, said first conduit means having an end thereof coupled to a said inlet port of said first container means; second container means for receiving plasma which has been separated from red blood cells in said first container means, said second container means having an upper end, the container means having a first, relatively wide diameter portion adjacent to said upper end thereof, a second relatively narrow portion defined below said first portion for receiving a blood coagulation factor precipitate from the plasma within said second container means and a third relatively wide portion defined below said second, relatively narrow portion so that said second, relatively narrow portion defines a relatively narrow passage for precipitate blood coagulation factor from said first portion to said third portion; and second conduit means having a first end thereof coupled to a said outlet port of said first container means and a second end thereof coupled to a said inlet port of said second container means for conveying plasma from said first container means to said second container means.</p>
    <p>19. Sierra, D. H., Brown, D. M., and Luck, E. E., Surgical adhesive material. U.S. Pat. No. 5,290,552 (1994) Assigned to Matrix Pharm Inc/Project Hear.</p>
    <p>20. Wadstroem, J., Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer. WO Patent 92/22,312 (1992) .</p>
    <p>21. Iwatsuki, M. and Hayashi, T., Silk-fibroin and human-fibrinogen adhesive composition. U.S. Pat. No. 4,818,291 (1989) Assigned to Ajinomoto Co Inc.</p>
    <p>22. Tse, D. C., Alpern, M., Enomoto, S. T., Garanchon, C. M., Liu, S. L., Mankarious, S. S., and Thomas, W. R., Topical fibrinogen complex. WO Application Patent 05067 (1993) Assigned to Baxter Int Inc.</p>
    <p>23. Edwardson, P. A. D., Fairbrother, J. E., Gardner, R. S., Hollingsbee, D. A., and Cederholm-Williams, S. A., Fibrin sealant compositions and method for utilizing same. EP (Application) Patent 592,242 (1993) Assigned to Squibb.</p>
    <p>24. Rose, E. and Dresdale, A., Method of preparing a cryoprecipitated suspension and use thereof. U.S. Pat. No. 4,928,603 (1990) Assigned to Columbia University. Claim 1: A method of preparing a cryoprecipitated suspension containing fibrinogen and Factor XIII useful as a precursor in the preparation of a fibrin glue which consists essentially of: (a) freezing fresh frozen plasma from a single donor which has been screened for blood transmitted diseases at about -80* C. for at least 6 hours, (b) raising the temperature of the frozen plasma so as to form a supernatant and a cryoprecipitated suspension containing fibrinogen and Factor XIII, and (c) recovering the cryoprecipitated suspension.</p>
    <p>Rose, E. and Dresdale, A., Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma. U.S. Pat. No. 4,627,879 (1986) Assigned to Columbia University. Summary: Prodn. of a fibrin glue comprises preparing a cryoprecipitated suspension contg. fibrinogen and Factor XIII by freezing fresh frozen plasma from a single donor which has been screened for blood transmitted diseases at -80 deg. C for at least 6 hrs., raising the temp. to form a supernatant and cryoprecipitated suspension contg. fibrinogen and Factor XIII, and recovering the suspension. A defined vol. of the suspension is applied to the desired site and a compsn. contg. thrombin is applied to cause the fibrinogen in the suspension to be converted to the fibrinogen glue, which then solidifies as a gel.</p>
    <p>25. Weis-Fogh, U., A Method and an Apparatus for preparing tissue repair promoting substances. WO (Application) Patent 88/02259 (1988).</p>
    <p>26. Alterbaum, R., Method and apparatus for use in preparation of fibrinogen from a patient's blood. U.S. Pat. No. 4,714,457 (1987). Claim 1: A method for use in the autologous preparation of fibrin glue wherein a patient's blood is separated in a centrifuge having cylindrical cups pivotally mounted to a rotor to obtain plasma and wherein the plasma is separated in the centrifuge to produce concentrated fibrinogen, comprising the steps of: (a) transferring the blood or plasma into a substantially flat packet; (b) fixing the packet containing the blood or plasma in a recess of a substantially cylindrical insert fixture assembly; (c) inserting said cylindrical-shaped insert fixture assembly in a cup of the centrifuge having a complementary cylindrical shape so that the insert fixture assembly is held snugly within said centrifuge cup; (d) centrifuging the blood or plasma contained within said packet fixed in said insert fixture assembly held in said centrifuge cup to separate the blood or plasma into components; and (e) forming fibrin glue from one of said separated components.</p>
    <p>27. Galanakis, D. K., Method of preparing autologous plasma fibrin and application apparatus therefore. U.S. Pat. No. 5,185,001 (1993) Assigned to Univ New York State Res Found.</p>
    <p>28. Eibl, J., Habison, G., Redl, H., and Seelich, T., Arrangement for applying a tissue adhesive. U.S. Pat. No. 4,735,616 (1988) Assigned to Immuno AG.</p>
    <p>29. Redl, H. and Habison, G., Apparatus for Applying a tissue adhesive. U.S. Pat. No. 4,631,055 (1986) Assigned to Immuno AG.</p>
    <p>30. Miller, C. H., Altshuler, J. H., and Arenberg, I. K., Fibrin glue delivery system. U.S. Pat. No. 4,874,368 (1989) Assigned to Micromedics.</p>
    <p>31. Avoy, D. R., Fibrinogen dispensing kit. U.S. Pat. No. 4,902,281 (1990) Assigned to Corus Med Corp.</p>
    <p>32. Morse, B. S., McNally, R. T., and Turner, A. D., Fibrin sealant delivery method. U.S. Pat. No. 5,219,328 (1993) Assigned to Cryolife.</p>
    <p>33. Headley, T. D., Plasmapheresis centrifuge bowl; disposable. U.S. Pat. No. 4,983,158 (1991) Assigned to Haemonetics Corp; Pages, E., Disposable centrifuge bowl for blood processing. U.S. Pat. No. 4,943,273 (1990); Latham, A., Jr., Apparatus for separating blood into components thereof. U.S. Pat. No. 4,303,193 (1981); Latham, A., Jr., Process for pheresis procedure and disposable plasma. U.S. Pat. No. 4,204,537 (1980); Latham, A., Jr., Process for pheresis procedure and disposable pheresis bowl therefor. U.S. Pat. No. 4,059,108 (1977); assigned to Haemonetics.</p>
    <p>34. Pall, D. B. and Gsell, T. C., Method for obtaining platelets. U.S. Pat. No. 5,258,126 (1993) Assigned to Pall Corp; Pall, D. B. and Gsell, T. C., Blood collection and processing system. U.S. Pat. No. 5,100,564 (1992) Assigned to Pall Corp.</p>
    <p>35. Pall, D. B., Gsell, T. C., Matkovich, V. I., and Bormann, T., System and method for processing biological fluid. U.S. Pat. No. 5,217,627 (1993) Assigned to Pall Corp; Pall, D. B., Gsell, T. C., and Muellers, B. T., Method for processing blood for human transfusion. U.S. Pat. No. 5,152,905 (1992) Assigned to Pall Corp; Eldegheidy, M. M., Automatic liquid component separator. U.S. Pat. No. 4,639,316 (1987) Assigned to Becton Dickinson &amp; Co.</p>
    <p>36. Process for the Manufacture of Hydrophilic High Molecular Weight Substances from Dextran Substances. GB Patent 854,715 (1965); Gelotte, E. B. and Soderquist, B. G. F., [Hydroxy compound copolymers dextran-epichlorhydrin] Verfahren zur Herstellung von Substi tutionsprodukten von Mischpolymerisaten. DD Patent 56,103 (1965); Beil, W., Hoeppner, A., Wolff, H. J., and Beil, H., [Verfahren zur Herstellung yon hochmolecularen hydrophilen Vernetzungsproducten von Polysacchariden oder deren Derivaten oder yon Polyvinylalkohol in Form yon Gelkoernern] High mol. wt. hydrophilic copolymer of a hydroxy group-contng., non-ionic polymer is obtd. in the form of gel grains by reacting the polymer, in the presence. DE Patent 1,443,359 (1962); assigned to Pharmacia.</p>
    <p>37. Rothman, U. S. and Jacobsson, S. A., Method for cleansing fluid discharging skin surfaces, wounds and mucous membranes and means for carrying out the method; dry particles of water-insoluble swellable polymer. U.S. Pat. No. 4,537,767 (1985) Assigned to Pharmacia AB; Rothman, U. S. and Jacobsson, S. A., Method for cleansing fluid discharging skin surfaces, wounds and mucous membranes and means for carrying out the method. U.S. Pat. No. 4,225,580 (1980) Assigned to Pharmacia AB.</p>
    <p>38. Hunziker, E. B., Method and compositions for the treatment and repair of defects or lesions in cartilage. U.S. Pat. No. 5,206,023 (1993) .</p>
    <p>39. Sarfarazi, F., Sarfarazi method of closing a corneal incision. U.S. Pat. No. 5,190,057 (1993); O'Donnell, F., E., Jr., Maremen, E., and Nalbandian, R. M., Intraocular lens implant and method of locating and adhering within the posterior chamber. U.S. Pat. No. 5,002,571 (1991).</p>
    <p>40. Sawyer, P. N., Collagen welding rod material for use in tissue welding. U.S. Pat. No. 5,156,613 (1992) Assigned to Interface Biomedical Laboratories.</p>
    <p>41. Sakamoto, I., Unigame, T., and Takagi, K., Hemostatic agent. U.S. Pat. No. 4,655,211 (1987) Assigned to Unitika KK.</p>
    <p>42. Zimmermann, E. and Schiele, U., Agent for sealing and healing wounds. U.S. Pat. No. 4,453,939 (1984) Assigned to Hormon-Chemie Munch; Stemberger, A., Gewebeverklebarre kollagene Wundauflage. EP Patent 102,773 (1983) Assigned to Dr. Ruhland Nachf. GmbH.</p>
    <p>43. Wehling, P., Method of enhancing the regeneration of injured nerves and adhesive pharmaceutical formulation therefor. U.S. Pat. No. 5,279,825 (1994) Assigned to Advanced Biofactures; Wehling, P., Method of enhancing the regeneration of injured nerves and adhesive pharmaceutical formulation therefor; supplying collagenase to the zone of nerve injury during regeneration. U.S. Pat. No. 5,173,295 (1992) Assigned to Advanced Biofactures.</p>
    <p>44. Lindblad, G. and Buckley, P., Composition and method for prevention of adhesions between body tissues. U.S. Pat. No. 5,190,759 (1993) Assigned to Kabi Pharmacia AB.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>Accordingly, one object of the present invention is to provide a novel method and apparatus for rapidly preparing a plasma concentrate from blood containing fibrinogen, prothrombin (the inactive precursor of thrombin) and other blood proteins, and platelets (thrombocytes) (citrate, heparin or other anticoagulant may be present in an amount sufficient to prevent initiation of clotting).</p>
    <p>A further object of the present invention is to provide a novel method and apparatus for rapidly preparing a plasma concentrate from a patient's own blood (autologous tissue sealant).</p>
    <p>A further object of the present invention is to provide a novel method and apparatus for rapidly preparing a concentrate from a patient's own blood while in the operating room (star autologous tissue sealant).</p>
    <p>A further object of the present invention is to provide a composition with physical, chemical and biological properties superior to plasma protein precipitate derived tissue sealants.</p>
    <heading>BRIEF DESCRIPTION OF THE DRAWINGS</heading> <p>A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:</p>
    <p>FIG. 1 shows an embodiment of a disposable cartridge in accordance with the present invention, employing plasma separation by open cell hydrophobic foam and plasma concentration by open cell foam with beads held thereto by electrostatic force;</p>
    <p>FIG. 2 shows an embodiment of a disposable cartridge in accordance with the present invention, employing plasma separation by sintered plastic barrier and plasma concentration by beads distributed in a trough;</p>
    <p>FIG. 3 shows an embodiment of a disposable cartridge in accordance with the present invention, employing plasma separation by annular chamber and plasma concentration by open cell foam with beads held thereto by electrostatic force;</p>
    <p>FIG. 4 shows an embodiment of a disposable cartridge in accordance with the present invention, employing plasma separation by felt mat and plasma concentration by beads impregnated into plastic discs;</p>
    <p>FIG. 5 depicts a single enlarged concentrator bead in a solution of low molecular weight and macromolecule components (e.g., plasma) in accordance with the present invention; and</p>
    <p>FIG. 6 shows an embodiment of a disposable cartridge in accordance with the present invention after centrifugation and during syringe withdrawal of the plasma concentrate;</p>
    <p>FIG. 7 shows an embodiment of the applicator in accordance with the present invention employing coaxial needles to allow mixing of the two components;</p>
    <p>FIG. 8 shows an embodiment of the applicator in accordance with the present invention employing an activator cartridge to allow application of single component fibrin sealant; and</p>
    <p>FIG. 9 graphically shows the relationship between the concentration of proteins and their molecular weight, for a protein solution or suspension concentrated 3 with beads having a molecular weight cutoff of 10 kDa in accordance with the present invention.</p>
    <heading>DESCRIPTION OF THE PREFERRED EMBODIMENTS</heading> <p>An inexpensive device with a disposable cartridge for preparation of tissue sealant is disclosed. The device is particularly applicable to stat preparation of autologous tissue sealant. The disposable cartridge may fit in the palm of the hand and is hermetically sealed to eliminate possible exposure to patient blood and ensure sterility. Methods of sealing tissue in which the tissue sealant is applied immediately after mixing platelet-rich plasma concentrate (from the device) with a solution of calcium and thrombin or in which the tissue sealant is applied immediately after physical or immobilized enzyme activation are disclosed.</p>
    <p>Preparation in the operating room of 5 cc sealant from 50 cc patient blood requires less than 15 minutes and only one simple operator step. There is no risk of tracking error because processing can be done in the operating room. Additional chemicals used in the plasma sealant and preparation thereof may be limited to anticoagulant (for example, citrate) and calcium salts (e.g., chloride).</p>
    <p>Adhesive and tensile strengths are comparable to pooled blood fibrin sealants that are available in Europe commercially. Antifibrinolytic agents (such as aprotinin) are not necessary because the tissue sealant contains high concentrations of natural inhibitors of fibrinolysis from the patient's blood. The tissue sealant also contains patient platelets and additional factors not present in available fibrin sealants that promote wound healing.</p>
    <p>The present (autologous) tissue sealant gels rapidly as it is mixed with calcium (and optionally bovine or human thrombin) while being applied to the wound. This sealant contains only FDA-approved or approvable components. In the present invention, a "tissue sealant" contains the components found in blood that contribute to clot formation, tissue adhesion and wound healing (preferably all such components in blood), and thus, is distinguished from prior "fibrin sealants" which typically contain only cryoprecipitated proteins and no platelets.</p>
    <p>The present invention concerns a method of making platelet-rich plasma (PRP) concentrate, which can then be combined with calcium/thrombin to make tissue sealant. The resulting gel is a composition that has never before been described in the scientific or patent literature.</p>
    <p>Referring now to the drawings, wherein like reference numerals designate identical or corresponding parts throughout the several views, and more particularly to FIG. 1 thereof, in a preferred embodiment of the present invention, citrated plasma is processed in two stages in a disposable centrifuge cartridge. In a first stage, platelet-rich plasma is separated from cells when centrifugal force causes red and white cells to lodge irreversibly in a first separator (e.g., a hydrophobic open cell foam). In a second stage, the platelet-rich plasma is concentrated by contact with a concentrator (e.g., dextranomer beads) that absorbs water, electrolytes and small proteins, leaving a platelet-rich plasma concentrate. Thus, the present method of making platelet-rich plasma comprises the steps of:</p>
    <p>(a) separating plasma and platelets from whole blood;</p>
    <p>(b) contacting the plasma and platelets with a concentrator to provide the concentrated platelet-rich plasma; and</p>
    <p>(c) separating the concentrated platelet-rich plasma from the concentrator.</p>
    <p>Preferably, the cartridge is disposable and sealed (e.g., see housing 1 in each of FIGS. 1 through 4), making contamination impossible. Where the method is performed in a sealed cartridge, the separating step (a) above may be conducted, for example, in a first chamber of the cartridge which is in fluid communication with the blood fill port (inlet). The plasma and platelets may then be contacted with a concentrator (e.g., in a second chamber of the cartridge in fluid communication with the first chamber) sufficiently to concentrate the plasma. An advantage of the sealed, disposable cartridge is that it can be used in the operating room, thus eliminating the possibility of tracking errors and contamination.</p>
    <p>In a further embodiment, the method is one for making autologous concentrated platelet-rich plasma, in which the method above for making concentrated platelet-rich plasma further comprises, prior to the separating step (a), collecting blood from a patient and adding an effective mount of citrate to inhibit coagulation (in accordance with standard methods), and injecting a standard quantity of blood (e.g., 50 cc) into the blood fill port (inlet) 5 of a cartridge 1.</p>
    <p>Plasma is separated from blood by a combination of conventional centrifugation technology and inventions for ease of separation of the packed cells from the plasma. Centrifuges which are capable of spinning at variable speeds up to 3,000-10,000 rpm in either direction and which are capable of being controlled by a microprocessor (i.e., for spinning at predetermined rates of rotation for predetermined lengths of time) are known and are easily adapted, if necessary, for use with the present apparatus for separating and concentrating plasma. Following injection of the whole blood, the operator starts the microprocessor-controlled centrifuge by push-button. All remaining steps until removal of the concentrate may be automatic.</p>
    <p>Although cells are conventionally separated from plasma by their property of packing into a cell mass during centrifugation (then typically aspirated), the cartridges are designed to effect rapid separation of the plasma into the next, concentrator chamber. In one embodiment (FIG. 1), red and white cells remain trapped in a hydrophobic open cell foam 14. In another embodiment (FIG. 4) red and white cells remain trapped in a felt annulus 7. In a third embodiment (FIG. 2) the cells pass through sinuous pathways in a sintered annulus 8 and remain trapped outside. In a fourth embodiment (FIG. 3) red and white cells migrate through a small gap 16 and remain trapped in an outer annulus by the force of gravity when the centrifuge stops.</p>
    <p>Optionally, the plasma may be contacted with dextranomer beads that have been bonded by electrostatic force with an open, hydrophobic cellular foam 15 (in accordance with the apparatus of FIGS. 1 and 3). When wetted the beads lose their electrostatic attraction and begin to swell. Alternatively, the plasma may be contacted with free dextranomer beads 2, e.g., in accordance with the apparatus of FIG. 2. The centrifuge may rotate briefly clockwise then counterclockwise a few times at a speed sufficient to evenly distribute the free dextranomer beads 2 outside the concentrator cup lip 3.</p>
    <p>The centrifuge may then spin at from 1,000 to 10,000 rpm, preferably 3,000 rpm, for one to ten minutes to separate platelet-rich plasma from cells. First, the whole blood passes through a pore 4 in the blood inlet 6 into the separation chamber. Cells may become trapped in a matrix 14 (as shown in FIG. 1), enmeshed in a matrix 7 (as shown in FIG. 4), or pass through sintered hydrophobic plastic or other porous material 8 (as shown in FIG. 2), leaving platelet-rich plasma in the chamber.</p>
    <p>The centrifuge may then be stopped for 15-90 seconds. Under the force of gravity, the platelet-rich plasma passes through an annulus (or through a hydrophilic filter 9) into the second chamber 10 (the lower chamber in FIGS. 1 through 4). This chamber may also be identified as a first concentrator chamber.</p>
    <p>In the first concentrator chamber, platelet-rich plasma comes into contact with the concentrator (e.g., dextranomer or polyacrylamide), either bonded by electrostatic force with an open, hydrophobic cellular foam 15 (FIGS. 1 and 3) or free beads 2 (FIG. 2) or beads embossed onto disc(s) 11 (FIG. 4). Dextranomer and polyacrylamide concentrators are commercially available (as SEPHADEX from Pharmacia and as BIO-GEL P from Bio-Rad Laboratories, respectively). Alternatively, instead of dextranomer or polyacrylamide absorbent beads, other concentrators, such as SEPHADEX moisture or water absorbants (available from Pharmacia), other polyacrylamide absorbants, silica gel, zeolites, dextramines, alginate gel, starch, cross-linked agarose, etc., in the form of beads or discs are also acceptable concentrators.</p>
    <p>In essence, any material that absorbs water (i.e., which is sufficiently dry to permit water absorption) and which does not significantly denature the proteins essential to blood clotting (e.g., fibrinogen and factor XIII) can be used as a concentrator, as can appropriately-selected membranes, which may also employ an osmotic gradient. Further, where the centrifuge has autoclave-like capabilities (i.e., the ability to rotate its contents at elevated temperatures and/or atmospheric pressures other than 1 atm), mechanical concentrators, such as an elevated temperature (e.g., a temperature of 30-80 C., preferably 35-60 C.) or a reduced pressure/vacuum (e.g., 0.1-500 Torr, preferably 1-200 Torr) may serve as a concentrator. However, beads employed as described both above and hereunder are the preferred concentrator.</p>
    <p>To maximize results, initial slow rotation of the centrifuge aids mixing (and thus contact) of the concentrator and the plasma. "Slow rotation" refers to a centrifuge speed of from 20 rpm to 500 rpm, preferably from 100 rpm to 300 rpm.</p>
    <p>The porosity and hydrophobicity of the porous wall 7, 8 or 14 are such that the low centrifugal force generated is sufficient to drive plasma up the wall but is not sufficient to overcome surface tension, and the plasma remains with the compartment at the inner surface.</p>
    <p>The beads 2 swell with water, ions, and low molecular weight proteins 51 (see FIG. 5). The size of the pores 52 in the concentrator bead 2 is chosen so that the higher molecular weight proteins 53 become concentrated in the space around the beads. Any commercially available bead concentrators for concentrating proteins having a molecular weight above a certain preselected molecular weight cutoff value may be used.</p>
    <p>As those of ordinary skill in protein chromatography understand, a "molecular weight cutoff" refers to pores in a matrix (e.g., SEPHADEX) which are distributed about a mean size. Moieties (e.g., proteins) more than, for example, 25-50% smaller than mean size diffuse into the bead rapidly, and moieties more than, for example, 25-50% larger than mean size do not diffuse into the bead. Proteins having a size within, for example, 25-50% of the mean size diffuse into the bead slowly (depending on the particular bead selected). Thus, a bead having a molecular weight cutoff of 10 kDa concentrates proteins according to molecular weight as shown graphically in FIG. 9.</p>
    <p>Consequently, in the present application, "high molecular weight compounds" refer to those compounds having a molecular weight greater than the preselected molecular weight cutoff value of the concentrator. Examples of high molecular weight proteins in plasma may include fibrinogen and factor XIII, depending on the selected molecular weight cutoff. Preferred concentrator materials include those beads or materials having a molecular weight cutoff value of 100 kDa, preferably 30 kDa and more preferably 5 kDa.</p>
    <p>It is important to note that the platelet-rich plasma concentrate contains all components of the original plasma, in either the original concentration (ions and compounds with molecular weight less than the concentrator cutoff) or at a greater concentration than naturally-occurring plasma (e.g., platelets and compounds with molecular weight more than the concentrator cutoff). The protein concentrate contains the same ion concentrations as the unconcentrated plasma.</p>
    <p>The quantity of beads is chosen so that the platelet rich plasma is concentrated by a desired amount, e.g., 3 (the approximate level of concentration achieved by a predetermined volume of fluid surrounding close-packed spheres in the same volume). When using DEBRISAN (trademark, Johnson and Johnson), approximately 2.6 gm is required per 10 cc plasma to achieve 3-fold concentration.</p>
    <p>After absorption of water and low molecular weight solutes into the concentrator, the rate of rotation is increased (e.g., to 1,000-10,000 rpm, preferably to about 3,000 rpm), forcing the concentrated platelet-rich plasma out through a filter 12 into an outer compartment. The centrifuge may then be stopped, and under the force of gravity, concentrated platelet-rich plasma may be collected in a bottom well 13. The concentrated platelet-rich plasma may be left for extended periods (e.g., hours) without spontaneous gelation or other deleterious effect.</p>
    <p>Concentrated platelet-rich plasma, ready for use, may then be removed into a syringe 16 as in FIG. 6.</p>
    <p>Thus, the present invention also concerns a method of sealing tissue, comprising the steps of contacting the present concentrated plasma with an activator (either a thrombin/calcium solution or disrupted platelets as described below) to provide an activated plasma concentrate, and applying the activated plasma concentrate to tissue in need of sealing.</p>
    <p>In one embodiment of the method of sealing tissue, a separately-prepared solution containing amounts of thrombin and calcium effective to coagulate the concentrated plasma may be combined with the concentrated plasma (in accordance with methods described in the literature for cryoprecipitated fibrinogen). Once combined, the solution and concentrated plasma rapidly gel to form a tissue sealant. An embodiment with features superior to any previously described is shown in FIG. 7. In the barrel of the syringe a cylindrical chamber 31 containing thrombin and calcium solution is surrounded by an annular chamber 32 containing concentrated platelet-rich plasma. Plunger 30 causes the solutions to exit the apparatus through a coaxial needle, 33 (thrombin) and 35 (concentrated plasma), and mix at the tip 36. An optional sleeve 34 ensures proper mixing, and may be retracted to expose premature gel for easy removal.</p>
    <p>In a further optional embodiment, a needle tip designed to activate fibrinogen may be used to apply a single-component concentrate (i.e., the concentrated plasma) without the use of added thrombin. In this embodiment, calcium is added to the concentrate immediately prior to or during its application to tissue in need of sealing. FIG. 8 shows a syringe 21 and applicator needle tip 23 separated by activator cartridge 22 through which platelet-rich plasma passes for activation by immobilized proteolytic enzyme, e.g., bovine thrombin.</p>
    <p>In a further optional embodiment, a needle tip designed to disrupt platelets may be used to apply a single-component concentrate (i.e., the concentrated plasma) without the use of thrombin. In this embodiment, calcium is added to the concentrate immediately prior to or during its application to tissue in need of sealing. FIG. 8 shows a syringe 21 and applicator needle tip 23 separated by activator cartridge 22 through which platelet-rich plasma passes for activation by, e.g., nylon wool.</p>
    <p>The present invention also concerns an apparatus for concentrating platelet-rich plasma, comprising:</p>
    <p>an inlet,</p>
    <p>a first chamber in fluid communication with the inlet, containing a first separator for separating plasma and platelets from whole blood, thus forming platelet-rich plasma,</p>
    <p>a second chamber in fluid communication with the first chamber, containing a concentrator for concentrating the platelet-rich plasma and a second separator for separating the concentrated platelet-rich plasma from the concentrator, and</p>
    <p>an outlet for withdrawing the concentrated platelet-rich plasma.</p>
    <p>In a further embodiment, the first separator comprises an open cell hydrophobic foam which traps red blood cells and white blood cells therein under surface tension force.</p>
    <p>In a further embodiment, the first separator comprises a porous plastic wall which allows passage of red blood cells and white blood cells therethrough under a centrifugal force, but does not permit passage of red blood cells and white blood cells in the absence of the centrifugal force.</p>
    <p>In a further embodiment, the first separator comprises an annulus at the top of the first chamber that allows red blood cells and white blood cells to pass into an outer annulus and be separated from plasma, maintained by gravity when the centrifuge stops.</p>
    <p>In a further embodiment of the apparatus, the concentrator may be embedded onto a paper disc, or onto a plurality of discs (of any commercially available material), or may stick electrostatically or by other forces to an open cell matrix.</p>
    <p>Many designs of a preferred embodiment of the present cartridge are envisioned (for example, FIGS. 1 through 4). The designs of the first and second chambers are largely independent, and may be combined into a single cartridge at will. All four designs shown have at least one separation chamber in fluid connection with at least one concentration chamber.</p>
    <p>The most preferred embodiment, FIG. 1, uses open cell hydrophobic foam 14 for separation of plasma from cells and effects plasma concentration by beads held by electrostatic force in an open cell foam 15. Another preferred embodiment, shown in FIG. 2, uses plasma separation by sintered plastic barrier 8 and plasma concentration by beads distributed in a trough 2. Another preferred embodiment, shown in FIG. 3, uses plasma separation by annular chamber 16 and plasma concentration by beads held by electrostatic force within open cell foam 15. Another preferred embodiment, shown in FIG. 4, uses plasma separation by felt mat 7 and plasma concentration by beads impregnated into plastic discs 12.</p>
    <p>Each separator can be used with each concentrator. The four separators may be combined with the three concentrators to give twelve possible arrangements for the disposable cartridge.</p>
    <p>A. Open Cell Hydrophobic Foam Plasma Separator and Dextranomer Bead in Open Cell Hydrophobic Foam Concentrator</p>
    <p>In FIG. 1, the ready cartridge is shown in the right half and the path of the liquid is shown by the dashed arrows on the left half. The entire chamber is radially symmetric except the septum 5 for the whole blood inlet. The receiving cup 6 holds blood until centrifugal force causes blood to pass through the filter 4. In the separation chamber, centrifugal force causes cells to pass into the open cell hydrophobic foam 14 and accumulate therein; continuing centrifugal force causes cells to migrate into the annulus of open cell foam and platelet rich plasma to remain within the separation chamber. The open cell hydrophobic foam 14 is a honeycomb-like hydrophobic material which allows fluids and small particles to flow freely (e.g., open cell polyurethane foam). Like a wetted sponge, the foam holds liquid against a certain head of pressure due to surface tension forces. Thus, blood cells or other suspended particulates remain entrapped within the foam when the centrifuge stops and separated platelet-rich plasma drains from the surface under the force of gravity. Foam can be either rigid or flexible and can be formed into the appropriate annular shape for the device by molding or die-cutting. The parts are sized so that the packed cell (e.g., erythrocyte and leukocyte) layer is fully contained within the outer open cell foam chamber, which retains the cells when the centrifuge stops.</p>
    <p>Concentration comes about when platelet-rich plasma contacts concentrator (e.g., dextranomer) beads 2 in the concentration chamber 10. These beads may be a molecular sieve used in chromatography (SEPHADEX, available from Pharmacia; BIO-GEL P, available from Bio-Rad Laboratories) and debriding (DEBRISAN, available from J&amp;J), or may comprise silica gel, zeolites, dextramines, alginate gel, starch, cross-linked agarose, etc. DEBRISAN appears similar to SEPHADEX G-25, and both are available commercially.</p>
    <p>The beads are held by static electric forces onto the surface of open cell hydrophobic foam 15. The open cell hydrophobic foam 15 is a honeycomb-like hydrophobic material. After the platelet-rich plasma has entered the concentration chamber 10, the cartridge 1 is gently rotated to mix platelet-rich plasma with concentrator beads 2. As the fluid penetrates the open foam 15, the beads lose their affinity for the foam and begin to swell. Foam 15 may be made from the same material as foam 14 (e.g., open cell polyurethane), but may have a different porosity. The porosity of foams 14 and 15 is selected empirically on the basis of the sizes and/or types of particles to be retained (e.g., cells by foam 14 and concentrator beads by foam 15). In commercially available open cell, three-dimensional polyurethane foams, porosity is known to be correlated to density (which is measured in, e.g., weight per cubic foot).</p>
    <p>After a few minutes (e.g., 1-10 min., preferably 3-5 min.), the concentration is complete. Note that concentration by approximately three times corresponds to fluid surrounding close-packed spheres; thus, three times concentration is optimal. Concentration of more than three times is possible, but to achieve best results, a second concentration chamber should be used for further concentration of plasma concentrated in a first chamber. Thus, concentration of nine times is possible for a three-chamber cartridge containing two concentration chambers.</p>
    <p>When concentration is complete, the centrifuge increases its rate of rotation and the increased centrifugal forces cause concentrated platelet-rich plasma to pass through the hydrophobic annulus 12. Sintered plastic 12 (e.g., POREX) is comprised of small particles of plastic fused to create a porous structure. Fluids and small particulates can flow freely through the tortuous pathways defined by the spaces between the fused plastic particles when the material is wet. If the plastic is not specially formulated or treated, the sintered plastic will be hydrophobic and when in the dry state will afford resistance to influx of water, more greatly as the size of the pathways is reduced. This property of "entry pressure" allows the wetting of the surface of a hydrophobic porous wall without substantial entry of fluid into the material. At greater pressure, i.e., when centrifugal force is increased, this resistive force is overcome and fluid breaks through the barrier to enter and pass through the porous wall.</p>
    <p>The centrifuge stops, and concentrated platelet-rich plasma runs to the bottom under the force of gravity and is ready to be removed through filter 13 as in FIG. 6.</p>
    <p>Finally, note that the concentrator cup 10 is shaped like an inverted funnel to vent the lower chamber to the upper chamber allowing displacement of air from the lower chamber by plasma.</p>
    <p>B. Hydrophobic Porous Wall Plasma Separator and Free Dextranomer Bead Concentrator</p>
    <p>In FIG. 2, the ready cartridge is shown in the right half and the path of the liquid is shown by the dashed arrows on the left half. The entire chamber is radially symmetric except the septum 5 for the whole blood inlet. The receiving cup 6 holds blood until centrifugal force causes blood to pass through the filter 4. In the separation chamber, centrifugal force causes cells to pass through the sinuous channels of filter 8 and accumulate in the outer annulus. The filter 8 (e.g., 80  POREX) is comprised of small particles of plastic fused to create a porous structure. Fluids and small particulates can flow freely through the tortuous pathways defined by the spaces between the fused plastic particles when the material is wet. If the plastic is not specially formulated or treated, the sintered plastic will be hydrophobic and when in the dry state will afford resistance to influx of water, more greatly as the size of the pathways is reduced. This property of "entry pressure" allows the wetting of the surface of a hydrophobic porous wall without substantial entry of fluid into the material. At greater pressure, i.e., when centrifugal force is increased (e.g., at 1000-10,000 rpm or higher), this resistive force is overcome and fluid breaks through the barrier to enter and pass through the porous wall. This leaves plasma and platelets in the chamber. The parts are sized so that the packed cell (e.g., erythrocyte and leukocyte) layer is fully contained within the filter and outer annulus. When the centrifuge stops and the platelet-rich plasma passes through the hydrophilic funnel filter 9, the force of gravity is insufficient to cause cells to pass through the filter 8 and back into the separation chamber.</p>
    <p>Hydrophilic funnel filter 9 separates the upper and lower compartments so that the loose beads cannot tumble into the upper compartment during shipping and handling. This material might, for example, be similar to that used for filter 8. In order that entry pressure not be so high as to preclude free drainage of plasma (by gravity) into the lower compartment after separation from blood cells, however, this material would preferably be of effective porosity minimally sufficient to ensure entrapment of beads in the concentrator chamber 10. The material would also most desirably be treated in a manner such as to render it more hydrophilic, (e.g., plasma or corona treated or blended or coated with surfactant) in order to further reduce entry pressure.</p>
    <p>Concentration comes about when platelet-rich plasma contacts concentrator beads 2 in the concentration chamber 10. These beads may be a molecular sieve used in chromatography (SEPHADEX, available from Pharmacia; BIO-GEL P, available from Bio-Rad Laboratories) and debriding (DEBRISAN, available from J&amp;J), or may comprise silica gel, zeolites, dextramines, alginate gel, starch, cross-linked agarose, etc. DEBRISAN appears similar to SEPHADEX G-25, and both are available commercially.</p>
    <p>The beads are sealed into the chamber, but may become unevenly distributed during shipment. A hydrophilic filter 9 keeps the beads in the concentrator chamber 10. Immediately after the addition of whole blood, the cartridge may be gently rotated and counter-rotated a few times to evenly distribute the beads behind the lip 3.</p>
    <p>After the platelet-rich plasma has entered the concentration chamber 10, the cartridge 1 is gently rotated to mix platelet-rich plasma with concentrator beads 2. For best results, it is important to keep the slurry in motion because of the tendency for protein to locally concentrate around each bead, retarding absorption. After a few minutes (e.g., 1-10 min., preferably 3-5 min.), the concentration is complete. Note that concentration by approximately three times corresponds to fluid surrounding close-packed spheres; thus, three times concentration is optimal. Concentration of more than three times is possible, but to achieve best results, a second concentration chamber should be used. Thus, concentration of nine times is possible for a three-chamber cartridge containing two concentration chambers.</p>
    <p>When concentration is complete, the centrifuge increases its rate of rotation and the increased centrifugal forces cause concentrated platelet-rich plasma to pass through the hydrophobic annulus. Finally, the centrifuge stops, and concentrated platelet-rich plasma runs to the bottom under the force of gravity and is ready to be removed.</p>
    <p>Finally, note that the concentrator cup 10 is shaped like an inverted funnel to vent the lower chamber to the upper chamber allowing displacement of air from the lower chamber by plasma.</p>
    <p>C. Annular Chamber Plasma Separator and Dextranomer Bead in Open Cell Hydrophobic Foam Concentrator</p>
    <p>In FIG. 3, similar to FIG. 1 in many respects, the ready cartridge is shown in the right half and the path of the liquid is shown by the dashed arrows on the left half. The entire chamber is radially symmetric except the septum 5 for the whole blood inlet. The receiving cup 6 holds blood until centrifugal force causes blood to pass through the filter 4. In the separation chamber, centrifugal force causes cells to pass above the lip 16 into an outer annular chamber and accumulate therein; continuing centrifugal force causes cells to migrate into the outer annulus and platelet rich plasma to remain within the separation chamber. The parts are sized so that the packed cell (e.g., erythrocyte and leukocyte) layer is fully contained within the outer annular chamber, which retains the cells when the centrifuge stops. When the centrifuge stops, the platelet-rich plasma flows into the concentrator chamber 10.</p>
    <p>Concentration comes about when platelet-rich plasma contacts concentrator beads 2 in the concentration chamber 10. These beads are a molecular sieve used in chromatography (SEPHADEX, available from Pharmacia; BIO-GEL P, available from Bio-Rad Laboratories) and debriding (DEBRISAN, available from J&amp;J), or may comprise silica gel, zeolites, dextramines, alginate gel, starch, cross-linked agarose, etc. DEBRISAN appears similar to SEPHADEX G-25, and both are available commercially.</p>
    <p>As in FIG. 1, the beads are held by static electric forces onto the surface of open cell hydrophobic foam 15. The open cell hydrophobic foam 15 is a honeycomb-like hydrophobic material. After the platelet-rich plasma has entered the concentration chamber 10, the cartridge 1 is gently rotated to mix platelet-rich plasma with concentrator (dextranomer) beads 2. As the fluid penetrates the open foam 15, the beads lose their affinity for the foam and begin to swell. For best results, it is important to keep the slurry in motion because of the tendency for protein to locally concentrate around each bead, retarding absorption. After several minutes, the concentration is complete. Note that concentration by approximately three times corresponds to fluid surrounding close-packed spheres; thus, three times concentration is optimal. Concentration of more than three times is possible, but to achieve best results, a second concentration chamber should be used. Thus, concentration of nine times is possible for a three-chamber cartridge containing two concentration chambers.</p>
    <p>When concentration is complete, the centrifuge increases its rate of rotation and the increased centrifugal forces cause concentrated platelet-rich plasma to pass through the hydrophobic annulus 12. Sintered plastic 12 is made of POREX, comprised of small particles of plastic fused to create a porous structure. Fluids and small particulates can flow freely through the tortuous pathways defined by the spaces between the fused plastic particles when the material is wet. If the plastic is not specially formulated or treated, the sintered plastic will be hydrophobic and when in the dry state will afford resistance to influx of water, more greatly as the size of the pathways is reduced. This property of "entry pressure" allows the wetting of the surface of a hydrophobic porous wall without substantial entry of fluid into the material. At greater pressure, i.e., when centrifugal force is increased (e.g., at 1000-10,000 rpm or higher), this resistive force is overcome and fluid breaks through the barrier to enter and pass through the porous wall.</p>
    <p>The centrifuge stops, and concentrated platelet-rich plasma runs to the bottom and is ready to be removed through filter 13 as in FIG. 6.</p>
    <p>Finally, note that the concentrator cup 10 is shaped like an inverted funnel to vent the lower chamber to the upper chamber allowing displacement of air from the lower chamber by plasma.</p>
    <p>D. Fibrous Matrix Plasma Separator and Dextranomer-Impregnated Disc Concentrator</p>
    <p>FIG. 4 is similar to the previous figures in many respects. Like FIG. 1, the ready cartridge is shown in the right half and the path of the liquid by the dashed arrows on the left half. The entire chamber is radially symmetric except the septum 5 (the whole blood inlet).</p>
    <p>Separation is done by driving cells into a felt or foam mat 7. The parts are sized so that the packed cell (e.g., erythrocyte and leukocyte) layer is fully contained within the felt or foam filter, which retains the cells when the centrifuge stops.</p>
    <p>In this design, even distribution of the dextranomer beads is assured by using plastic discs embossed with dextranomer beads. This can be done either with heat or solvent softening of the plastic followed by dipping in dextranomer beads or affixing beads to the plastic with adhesive. As the beads swell they detach from the discs. Separation of the concentrated platelet-rich plasma is done as in the above description of the present method of making concentrated platelet-rich plasma.</p>
    <p>E. Method of Manufacture of the Disposable Cartridge</p>
    <p>The various rigid plastic components comprising the cartridge are manufactured by injection molding or by pressure- or vacuum-forming, assembled and sealed by conventional methods (e.g., either by adhesives or welding). From FIGS. 1 through 4 it will be apparent to one skilled in the art of plastics fabrication that manufacture is relatively simple and inexpensive. The final assembled product is packaged, radiation sterilized and ready for distribution.</p>
    <p>F. Plasma Concentrate, Platelet-rich plasma Concentrate and Tissue Sealant</p>
    <p>The present invention also concerns a plasma concentrate, prepared by the present process. The present plasma concentrate may be platelet-rich, platelet-poor or platelet-free (i.e., the platelet concentration is not limited), but is preferably platelet-rich. The concentration of platelets can be controlled by the sedimentation rate, in accordance with known procedures and/or known platelet sedimentation behavior. Preferably, the plasma concentrate is autologous (administered to the patient from whom the whole blood was taken).</p>
    <p>In one embodiment, the present plasma concentrate comprises platelets, from 5 to 400 mg/ml of fibrinogen, from 0.5 to 35 mg/ml of fibronectin, and a physiologically acceptable carrier comprising water and physiologically acceptable inorganic and organic ions in a physiologically acceptable concentration. In a preferred embodiment, the plasma concentrate is prepared from whole blood, and platelets are concentrated at least one-and-one-half times relative to the concentration of platelets in unconcentrated plasma from the same whole blood.</p>
    <p>The present plasma concentrate may further contain a compound selected from the group consisting of an antibiotic, a collagen fleece, collagenase, hyaluronic acid, a wound-healing factor, zinc ions in an amount effective to decrease coagulation time of said plasma, and a biologically acceptable dye. A preferred biologically acceptable dye is disulphine blue, contained in an amount sufficient to visibly detect the plasma concentrate during its application to tissue. In a preferred embodiment, the plasma concentrate further comprises a pharmaceutically active compound, particularly an antibiotic to reduce the probability of infection by extraneous microorganisms.</p>
    <p>The present invention also concerns a tissue sealant, comprising the present plasma concentrate and an activator. Preferably, the plasma concentrate in the present tissue sealant is platelet-rich plasma concentrate.</p>
    <p>In one embodiment of the present tissue sealant, the activator is a mixture of thrombin and calcium in amounts sufficient to permit gelation of the plasma concentrate. In a further embodiment, the activator is autologous thrombin and platelets.</p>
    <p>G. Apparatus for and Method of Mixing Two-Component Fibrin Sealant</p>
    <p>Parallel syringes with the two components (e.g., concentrated platelet-rich plasma and calcium/thrombin solution) converge on a coaxial needle with mixing of the components at the application site, thus avoiding premature gelation; see FIG. 7. In the barrel of the syringe a cylindrical chamber 31 containing thrombin and calcium solution is surrounded by an annular chamber 32 containing concentrated platelet-rich plasma. Plunger 30 causes the solutions to exit the apparatus through coaxial needles and mix at the tip 36. An optional sleeve 34 ensures proper mixing, and may be retracted to expose premature gel for easy removal.</p>
    <p>H. Dispenser/Activator for Platelet-Rich Plasma Concentrate</p>
    <p>Most users of fibrin sealants have resorted to the use of bovine thrombin to induce gelation. In a preferred embodiment of the present invention, it is desirable to avoid excessive use of bovine proteins in the final preparation. Thus, a method and apparatus employing a small amount of bovine or other thrombogenic enzyme to trigger the autocatalytic activation of the coagulation process is envisioned. FIG. 8 shows a syringe 21 and applicator needle tip 23 separated by activator cartridge 22 through which platelet-rich plasma passes for activation by immobilized thrombin to convert fibrinogen to fibrin.</p>
    <p>In a further optional embodiment, a needle designed to disrupt platelets may be used to apply a single-component concentrate (i.e., the concentrated plasma) without the use of thrombin. FIG. 8 shows a syringe 21 and applicator needle tip 23 separated by activator cartridge 22 through which platelet-rich plasma passes for activation by, e.g., nylon wool. In this embodiment, calcium is added to the concentrate immediately prior to or during its application to tissue in need of sealing.</p>
    <p>A porous membrane or other material with high exposed surface to void volume ratio can be derivitized with thrombin or other thrombogenic or thrombin-like enzyme by known methods. The derivatized membrane is fitted between syringe and applicator needle.</p>
    <p>In a separate but related embodiment, glass wool, nylon wool or collagen sponge or another material may be used in a similar configuration to cause eversion of the platelets, known to initiate coagulation.</p>
    <p>In a separate but related embodiment, concentrated plasma may be kept cold to prevent gelation. After application, the heat of the living tissue will initiate gelation.</p>
    <p>A big problem with prior precipitation methods is that the fibrinogen must be reconstituted. This is difficult and may take hours, and only a relatively low concentration is achievable. Thus not only does the present invention allow more rapid availability, a surgeon can decide that "this one is a bleeder" and have sealant in 15 minutes. Previous technology requires that the surgeon order fibrin glue before the procedure begins.</p>
    <p>The present concentrated platelet-rich plasma can be left in the device until needed, for hours if necessary, without spontaneous gelation.</p>
    <p>Other autologous precipitation methods require that blood be drawn days in advance to allow time so that there is time for processing. Besides the inconvenience, this procedure allows the possibility of tracking errors and thus infection.</p>
    <p>Generally, a proteolysis inhibitor such as aprotinin is added to the fibrinogen component of fibrin glues. (Academic opinion is actually divided on whether this is necessary; need has never been proven rigorously.) The present methods for producing concentrated PRP retain the natural inhibitors which are evidently lost in precipitation steps.</p>
    <p>Fibrinogen from fresh plasma produces a mechanically superior gel (based on the general properties of proteins damaged by precipitation). Platelets (contained in the present plasma concentrate) are useful for wound healing (many references available). Thus, an advantage of the present technology is that it provides better wound healing than conventional fibrin glues, which do not contain platelets.</p>
    <p>Surgeons, particularly in the U.S., are likely to use bovine thrombin to "activate" the present tissue sealant. This is not a regulatory problem because bovine thrombin is available and is used routinely in surgery. However, the present invention provides a dispenser that activates prothrombin present in the concentrated platelet-rich plasma and/or that disrupt platelets so that clotting is initiated by one or more components in the concentrated plasma.</p>
    <p>The present tissue sealant and autologous tissue sealant do more than merely seal the wound and adhere the damaged structures. In particular, the present autologous tissue sealant contains the patient's own living thrombocytes and wound healing factors, and thus, it nurtures the healing process. Other advantages of the present tissue sealant include the presence of attachment factors which (i) improve adhesion to damaged tissue and (ii) promote cellular infiltration. In the present autologous tissue sealant, which is made from the patient's own blood, important advantages include the ease, speed and convenience of preparation (it may be prepared in the operating room immediately before use). Furthermore, the optional absence of bovine thrombin in the present autologous tissue sealant avoids immune system and foreign body reactions and eliminates disease transmission (i.e., from the bovine thrombin source).</p>
    <p>I. Separator and Method for Separating Particulates from Suspensions</p>
    <p>In a further aspect of the present invention, a separator and a general method for separating particulates from suspensions is envisioned. Separating particulates from biological fluids (such as blood and plasma) is a common problem in the laboratory. A disposable cartridge containing a separation chamber (i.e., the first chamber in the apparatus used for preparing the present concentrated plasma) allows cellular and dense particle separation--basically anything that moves in response to centrifugal force.</p>
    <p>Thus, the present apparatus for separating particulates from a liquid suspension comprises:</p>
    <p>an inlet,</p>
    <p>a first chamber in fluid communication with the inlet, containing a first separator for separating particulates from the liquid suspension, thus forming a particulate-free liquid, and</p>
    <p>an outlet for withdrawing the liquid.</p>
    <p>A "particulate-free liquid" is one which is substantially free of insoluble particles, preferably those insoluble particles having an average size above a pre-selected value (e.g., from 500 to 20 , or any value for which filters or other devices are available for removing such insoluble particles; e.g., 250 , 100 , 80 , 50 , etc.).</p>
    <p>J. Concentrator and Method for Concentrating Macromolecule Solutions</p>
    <p>In an even further aspect of the present invention, a concentrator and method for concentrating macromolecule solutions based on the design of the concentrator (or second) chamber used in the apparatus for preparing the present concentrated plasma is envisioned. SEPHADEX (trademark, Pharmacia), for example, is rarely used for concentrating macromolecule solutions. The device may not concentrate to dryness, but is useful for concentration of proteins (or any high molecular weight solution), preferably by a factor of three times or a multiple of three times, depending on the number of concentrator chambers in the apparatus.</p>
    <p>Thus, the present apparatus for concentrating a solution of a substance having a molecular weight greater than a predetermined value (i.e., macromolecule solution) comprises:</p>
    <p>an inlet,</p>
    <p>a chamber in fluid communication with the inlet, containing a concentrator for concentrating the solution and a separator for separating the solution from the concentrator, and</p>
    <p>an outlet for withdrawing the concentrated solution.</p>
    <p>Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limited thereof.</p>
    <heading>EXAMPLE 1</heading> <p>Using a cartridge as shown in either FIGS. 1, 2, 3 or 4, and following the procedure below, a concentrated platelet-rich plasma and tissue sealant can be prepared:</p>
    <p>I. Collect blood from patient using standard citrate anticoagulant.</p>
    <p>II. Inject a standard quantity of blood (e.g., 50 cc) in to the blood fill port of the disposable cartridge. The cartridge is sealed making contamination impossible. It will be used in the operating room making tracking errors impossible.</p>
    <p>III. The operator then starts the microprocessor-controlled centrifuge by push-button. All remaining steps until removal of the concentrate are automatic.</p>
    <p>IV. (Optional step for designs incorporating free concentrator beads, FIG. 2) The centrifuge rotates briefly clockwise then counterclockwise a few times at a speed sufficient to evenly distribute the free dextranomer beads outside the concentrator cup lip.</p>
    <p>V. The centrifuge spins at 3,000 rpm for one to ten minutes to separate platelet-rich plasma from cells. The whole blood passes through a pore in the blood receiver chamber into the separation chamber.</p>
    <p>VI. The centrifuge stops for 15-90 seconds. Under the force of gravity the platelet-rich plasma passes into the lower chamber, or concentrator chamber, (optionally by going through a through a hydrophilic filter, appropriate when free beads are present in the concentrator chamber as in FIG. 2).</p>
    <p>VII. In the concentrator chamber platelet-rich plasma comes into contact with beads bonded by electrostatic force to an open cell foam (cartridge of FIGS. 1 and 3), free concentrator beads (cartridge of FIG. 2), or beads embossed onto discs (cartridge of FIG. 4). Slow rotation of the centrifuge aids mixing. The porosity and hydrophobicity of the porous wall are such that the low centrifugal force generated is not sufficient to overcome surface tension and the plasma remains within the compartment at the inner surface. The beads swell with water, ions and low molecular weight proteins (i.e., those proteins having a molecular weight below the cutoff value). The pore size of the beads is so chosen that the proteins become concentrated in the space around the beads. The quantity of beads is chosen so that the platelet-rich plasma is concentrated the desired amount, e.g., 3. When using DEBRISAN, approximately 2.6 gm is required per 10 cc plasma to achieve 3-fold concentration. The protein concentrate contains the same ion concentrations as the unconcentrated plasma.</p>
    <p>VIII. The rate of rotation is increased forcing the concentrated platelet-rich plasma out through the filter into the outer compartment.</p>
    <p>IX. The centrifuge stops, and under the force of gravity concentrated platelet-rich plasma collects in the bottom. The concentrated platelet-rich plasma may be left for extended periods (hours) without spontaneous gelation.</p>
    <p>X. Concentrated platelet-rich plasma is removed into a syringe.</p>
    <p>XI. (Optional.) Thrombin/calcium solution is prepared separately.</p>
    <p>XII. Using a variety of methods described in the literature for cryoprecipitated fibrinogen, the two solutions are combined and rapidly gel to form the TISSUE SEALANT.</p>
    <p>XIII. (Optional; substitute for XI and XII.) Using a needle tip designed to disrupt platelets, a single-component concentrate may be applied without the use of bovine thrombin.</p>
    <p>A comparison of the properties of the present tissue sealant and prior tissue sealant prepared from cryoprecipitated fibrin is shown in the Table below:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE______________________________________Concentrations of Tissue Sealant CompositionsBlood     Precipitate Fibrin                    AutologousComponent Glue           Concentrated PRP (3X)______________________________________Ions      per reconstitution                    identical to patient     solution       plasmaPlatelets none           3X plasma                    concentrationProteins  only proteins that                    all plasma proteins     cryoprecipitate;                    at normal (less than     fibrinogen, factor                    5 kDa) or 3X normal     XIII, fibronectin,                    (more than 5 kDa)     albumin, plasminogen                    concentrationsAlbumin   10-25 mg/ml    100-165 mg/mlFactor XIII     75 g/ml    30-60 g/mlFibrinogen     70-110 mg/ml   5-14 mg/mlFibronectin     2-9 mg/ml      0.5-1.2 mg/mlPlasminogen     20-60 g/ml 600 g/mlAprotinin 1,500 KIU/ml   0 KIU/ml______________________________________</pre>
    
    <p>The present tissue sealant also appears to show similar tensile strength to that of cryoprecipitated fibrin tissue sealant. The adhesive strength provided by the present tissue sealant is believed to be superior to that of cryoprecipitated fibrin tissue sealant because fibrinogen and other important proteins are not denatured by the present process.</p>
    <p>A key advantage of the present invention is the presence of platelets. Adhesion of the platelets to collagen III fibrils leads to platelet aggregation, promoted by 5-hydroxytryptamine and epinephrine released from the platelets. Other growth and healing factors are released by the platelets. Platelet-derived growth factor is a mitogen for fibroblasts and smooth muscle cells. Platelet factors stimulate neovascularization, especially when the area is anoxic. Platelets also make fibrin more resistant to mechanical shear forces and to fibrinolysis.</p>
    <p>It is possible that for certain applications lesser numbers of platelets may be desirable. The invention may be adjusted to achieve this outcome. Because of their low mass compared with other blood cells, a preponderance of platelets is preserved in the final products when conditions are chosen to minimally separate the bulk of said more massive cells from whole blood. For example, a 4-inch diameter cartridge, 1 inch in height and fitted with a sintered plastic wall as in FIG. 2 will separate most of the blood cells from 50 cc of whole blood when centrifuged for 3 minutes at 2,000 rpm. By increasing the speed to 5,000 rpm and the time to 15 minutes, most of the platelets are also sedimented through the porous walls to yield plasma depleted of platelets. Such platelet depleted plasma may be desirable if, for example, it were desired that the plasma or concentrate derived therefrom should be processed by filtration through a sterile submicron membrane to render the final product suitable for storage for an extended time (days).</p>
    <p>Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.</p>
    <p>45. See, for example, DelRossi, A. J., A. C. Cernaianu, R. A. Vertrees, C. J. Wacker, S. J. Fuller, J. Cilley Jr., and W. A. Baldino. "Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass." J Thorac Cardiovasc Surg 100 (2 1990): 281-6.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US2553004">US2553004</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 11, 1949</td><td class="patent-data-table-td patent-date-value">May 15, 1951</td><td class="patent-data-table-td ">Rabatine Michael</td><td class="patent-data-table-td ">Dividing protractor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3453364">US3453364</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 12, 1964</td><td class="patent-data-table-td patent-date-value">Jul 1, 1969</td><td class="patent-data-table-td ">Pharmacia Ab</td><td class="patent-data-table-td ">Therapeutic infusion and injection composition containing hydroxyalkyl dextran</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3972812">US3972812</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 8, 1975</td><td class="patent-data-table-td patent-date-value">Aug 3, 1976</td><td class="patent-data-table-td ">Becton, Dickinson And Company</td><td class="patent-data-table-td ">Blood serum separation filter disc</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4059108">US4059108</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 15, 1975</td><td class="patent-data-table-td patent-date-value">Nov 22, 1977</td><td class="patent-data-table-td ">Haemonetics Corporation</td><td class="patent-data-table-td ">Process for pheresis procedure and disposable pheresis bowl therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4204537">US4204537</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 27, 1977</td><td class="patent-data-table-td patent-date-value">May 27, 1980</td><td class="patent-data-table-td ">Haemonetics Corporation</td><td class="patent-data-table-td ">Process for pheresis procedure and disposable plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4225580">US4225580</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 2, 1975</td><td class="patent-data-table-td patent-date-value">Sep 30, 1980</td><td class="patent-data-table-td ">Pharmacia Aktiebolag</td><td class="patent-data-table-td ">Method for cleansing fluid discharging skin surfaces, wounds and mucous membranes and means for carrying out the method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4294707">US4294707</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 19, 1980</td><td class="patent-data-table-td patent-date-value">Oct 13, 1981</td><td class="patent-data-table-td ">Terumo Corporation</td><td class="patent-data-table-td ">Method for separating blood and a barrier device therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4298598">US4298598</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 4, 1980</td><td class="patent-data-table-td patent-date-value">Nov 3, 1981</td><td class="patent-data-table-td ">Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte</td><td class="patent-data-table-td ">Tissue adhesive</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4300717">US4300717</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 27, 1980</td><td class="patent-data-table-td patent-date-value">Nov 17, 1981</td><td class="patent-data-table-td ">Haemonetics Corporation</td><td class="patent-data-table-td ">Rotary centrifuge seal</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4303193">US4303193</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 22, 1979</td><td class="patent-data-table-td patent-date-value">Dec 1, 1981</td><td class="patent-data-table-td ">Haemonetics Corporation</td><td class="patent-data-table-td ">Apparatus for separating blood into components thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4362567">US4362567</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 4, 1980</td><td class="patent-data-table-td patent-date-value">Dec 7, 1982</td><td class="patent-data-table-td ">Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte</td><td class="patent-data-table-td ">Tissue adhesive</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4377572">US4377572</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 7, 1981</td><td class="patent-data-table-td patent-date-value">Mar 22, 1983</td><td class="patent-data-table-td ">Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte</td><td class="patent-data-table-td ">Tissue adhesive</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4427650">US4427650</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 7, 1982</td><td class="patent-data-table-td patent-date-value">Jan 24, 1984</td><td class="patent-data-table-td ">Serapharm Michael Stroetmann</td><td class="patent-data-table-td ">Fibrinogen with thrombin or prothrombin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4427651">US4427651</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 7, 1982</td><td class="patent-data-table-td patent-date-value">Jan 24, 1984</td><td class="patent-data-table-td ">Serapharm Michael Stroetmann</td><td class="patent-data-table-td ">Enriched plasma derivative for enhancement of wound closure and coverage</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4442655">US4442655</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 25, 1982</td><td class="patent-data-table-td patent-date-value">Apr 17, 1984</td><td class="patent-data-table-td ">Serapharm Michael Stroetmann</td><td class="patent-data-table-td ">Fibrinogen-containing dry preparation, manufacture and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4453939">US4453939</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 11, 1982</td><td class="patent-data-table-td patent-date-value">Jun 12, 1984</td><td class="patent-data-table-td ">Hormon-Chemie Munchen Gmbh</td><td class="patent-data-table-td ">Fibrinogen, factor xiii, thrombin, collagen carrier</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4537767">US4537767</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 24, 1982</td><td class="patent-data-table-td patent-date-value">Aug 27, 1985</td><td class="patent-data-table-td ">Pharmacia Aktiebolag</td><td class="patent-data-table-td ">Method for cleansing fluid discharging skin surfaces, wounds and mucous membranes and means for carrying out the method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4627879">US4627879</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 3, 1985</td><td class="patent-data-table-td patent-date-value">Dec 9, 1986</td><td class="patent-data-table-td ">The Trustees Of Columbia University In The City Of New York</td><td class="patent-data-table-td ">Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4631055">US4631055</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 26, 1985</td><td class="patent-data-table-td patent-date-value">Dec 23, 1986</td><td class="patent-data-table-td ">Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte</td><td class="patent-data-table-td ">Disposable syringe bodies, joining pieces; human or animal proteins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4632761">US4632761</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 15, 1983</td><td class="patent-data-table-td patent-date-value">Dec 30, 1986</td><td class="patent-data-table-td ">W. R. Grace &amp; Co.</td><td class="patent-data-table-td ">Centrifugal microconcentrator and methods for its use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4639316">US4639316</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 14, 1984</td><td class="patent-data-table-td patent-date-value">Jan 27, 1987</td><td class="patent-data-table-td ">Becton, Dickinson And Company</td><td class="patent-data-table-td ">Automatic liquid component separator</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4650678">US4650678</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 10, 1984</td><td class="patent-data-table-td patent-date-value">Mar 17, 1987</td><td class="patent-data-table-td ">Behringwerke Aktiengesellschaft</td><td class="patent-data-table-td ">Readily dissolvable lyophilized fibrinogen formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4655211">US4655211</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 8, 1985</td><td class="patent-data-table-td patent-date-value">Apr 7, 1987</td><td class="patent-data-table-td ">Unitika Ltd.</td><td class="patent-data-table-td ">Hemostatic agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4672969">US4672969</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 6, 1983</td><td class="patent-data-table-td patent-date-value">Jun 16, 1987</td><td class="patent-data-table-td ">Sonomo Corporation</td><td class="patent-data-table-td ">Controlled adsorption for surgery and open injuries</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4714457">US4714457</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 15, 1986</td><td class="patent-data-table-td patent-date-value">Dec 22, 1987</td><td class="patent-data-table-td ">Robert Alterbaum</td><td class="patent-data-table-td ">Method and apparatus for use in preparation of fibrinogen from a patient&#39;s blood</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4735616">US4735616</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 17, 1986</td><td class="patent-data-table-td patent-date-value">Apr 5, 1988</td><td class="patent-data-table-td ">Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte</td><td class="patent-data-table-td ">Arrangement for applying a tissue adhesive</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4735726">US4735726</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 28, 1987</td><td class="patent-data-table-td patent-date-value">Apr 5, 1988</td><td class="patent-data-table-td ">E. I. Du Pont De Nemours And Company</td><td class="patent-data-table-td ">Plasmapheresis by reciprocatory pulsatile filtration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4755301">US4755301</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 12, 1986</td><td class="patent-data-table-td patent-date-value">Jul 5, 1988</td><td class="patent-data-table-td ">W. R. Grace &amp; Co.</td><td class="patent-data-table-td ">Centrifuging retentate reservoir having attached semipermeable membrane filter and cup to expel retentate into cup</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4770779">US4770779</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 1, 1987</td><td class="patent-data-table-td patent-date-value">Sep 13, 1988</td><td class="patent-data-table-td ">Terumo Corporation</td><td class="patent-data-table-td ">Apparatus for separating blood</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4818291">US4818291</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 10, 1987</td><td class="patent-data-table-td patent-date-value">Apr 4, 1989</td><td class="patent-data-table-td ">Ajinomoto Co., Inc.</td><td class="patent-data-table-td ">Silk-fibroin and human-fibrinogen adhesive composition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4832851">US4832851</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 2, 1987</td><td class="patent-data-table-td patent-date-value">May 23, 1989</td><td class="patent-data-table-td ">W. R. Grace &amp; Co.</td><td class="patent-data-table-td ">Proteins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4874368">US4874368</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 25, 1988</td><td class="patent-data-table-td patent-date-value">Oct 17, 1989</td><td class="patent-data-table-td ">Micromedics, Inc.</td><td class="patent-data-table-td ">Fibrin glue delivery system</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4879031">US4879031</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 6, 1988</td><td class="patent-data-table-td patent-date-value">Nov 7, 1989</td><td class="patent-data-table-td ">Dideco S.P.A.</td><td class="patent-data-table-td ">Blood centrifugation cell</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4902281">US4902281</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 16, 1988</td><td class="patent-data-table-td patent-date-value">Feb 20, 1990</td><td class="patent-data-table-td ">Corus Medical Corporation</td><td class="patent-data-table-td ">Separately dispensing each biological fluid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4928603">US4928603</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 6, 1988</td><td class="patent-data-table-td patent-date-value">May 29, 1990</td><td class="patent-data-table-td ">The Trustees Of Columbia University In The City Of New York</td><td class="patent-data-table-td ">Method of preparing a cryoprecipitated suspension and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4943273">US4943273</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 5, 1989</td><td class="patent-data-table-td patent-date-value">Jul 24, 1990</td><td class="patent-data-table-td ">Haemonetics Corporation</td><td class="patent-data-table-td ">Disposable centrifuge bowl for blood processing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4983157">US4983157</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 13, 1989</td><td class="patent-data-table-td patent-date-value">Jan 8, 1991</td><td class="patent-data-table-td ">Ceramics Process Systems Corp.</td><td class="patent-data-table-td ">Centrifugation system using static layer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4983158">US4983158</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 15, 1989</td><td class="patent-data-table-td patent-date-value">Jan 8, 1991</td><td class="patent-data-table-td ">Haemonetics Corporation</td><td class="patent-data-table-td ">Plasmapheresis centrifuge bowl</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4985153">US4985153</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 23, 1989</td><td class="patent-data-table-td patent-date-value">Jan 15, 1991</td><td class="patent-data-table-td ">Asahi Medical Co., Ltd.</td><td class="patent-data-table-td ">Method for separating blood into blood components, and blood components separator unit</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5000970">US5000970</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 30, 1989</td><td class="patent-data-table-td patent-date-value">Mar 19, 1991</td><td class="patent-data-table-td ">Horizons International Foods, Inc.</td><td class="patent-data-table-td ">Process for preparing reheatable french fried potatoes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5002571">US5002571</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 6, 1989</td><td class="patent-data-table-td patent-date-value">Mar 26, 1991</td><td class="patent-data-table-td ">Donnell Jr Francis E O</td><td class="patent-data-table-td ">Human eye</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5030215">US5030215</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 3, 1990</td><td class="patent-data-table-td patent-date-value">Jul 9, 1991</td><td class="patent-data-table-td ">Cryolife, Inc.</td><td class="patent-data-table-td ">Preparation of fibrinogen/factor XIII precipitate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5045048">US5045048</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 29, 1990</td><td class="patent-data-table-td patent-date-value">Sep 3, 1991</td><td class="patent-data-table-td ">Haemonetics Corporation</td><td class="patent-data-table-td ">Rotary centrifuge bowl and seal for blood processing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5071570">US5071570</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 19, 1990</td><td class="patent-data-table-td patent-date-value">Dec 10, 1991</td><td class="patent-data-table-td ">Terumo Corporation</td><td class="patent-data-table-td ">Centrifugation; separation through connecting tubes; returning part of platelet-deficient plasma as nutrient source for red corpuscles</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5100564">US5100564</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 6, 1990</td><td class="patent-data-table-td patent-date-value">Mar 31, 1992</td><td class="patent-data-table-td ">Pall Corporation</td><td class="patent-data-table-td ">Blood bags, connectors, filters, container for centrifuging, polybutylene terephthalate grafted with hydroxy or acid containing acrylic monomer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5112484">US5112484</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 11, 1990</td><td class="patent-data-table-td patent-date-value">May 12, 1992</td><td class="patent-data-table-td ">Zuk, Inc.</td><td class="patent-data-table-td ">Filtration apparatus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5137832">US5137832</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 2, 1991</td><td class="patent-data-table-td patent-date-value">Aug 11, 1992</td><td class="patent-data-table-td ">Becton Dickinson &amp; Company</td><td class="patent-data-table-td ">Heating, centrifuging</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5141645">US5141645</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 5, 1991</td><td class="patent-data-table-td patent-date-value">Aug 25, 1992</td><td class="patent-data-table-td ">Terumo Corporation</td><td class="patent-data-table-td ">Separate containers for each component</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5152905">US5152905</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 6, 1990</td><td class="patent-data-table-td patent-date-value">Oct 6, 1992</td><td class="patent-data-table-td ">Pall Corporation</td><td class="patent-data-table-td ">Centrifuging, filtration to block red blood cells, separation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5156613">US5156613</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 13, 1991</td><td class="patent-data-table-td patent-date-value">Oct 20, 1992</td><td class="patent-data-table-td ">Interface Biomedical Laboratories Corp.</td><td class="patent-data-table-td ">Applying optical or RF energy to melt collagen filler and adjacent biological tissue causing mixing; thus joining, repairing or rebuilding</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5173295">US5173295</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 5, 1990</td><td class="patent-data-table-td patent-date-value">Dec 22, 1992</td><td class="patent-data-table-td ">Advance Biofactures Of Curacao, N.V.</td><td class="patent-data-table-td ">Method of enhancing the regeneration of injured nerves and adhesive pharamaceutical formulation therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5185001">US5185001</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 18, 1990</td><td class="patent-data-table-td patent-date-value">Feb 9, 1993</td><td class="patent-data-table-td ">The Research Foundation Of State University Of New York</td><td class="patent-data-table-td ">Method of preparing autologous plasma fibrin and application apparatus therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5190057">US5190057</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 13, 1991</td><td class="patent-data-table-td patent-date-value">Mar 2, 1993</td><td class="patent-data-table-td ">Faezeh Sarfarazi</td><td class="patent-data-table-td ">Sarfarazi method of closing a corneal incision</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5190759">US5190759</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 21, 1990</td><td class="patent-data-table-td patent-date-value">Mar 2, 1993</td><td class="patent-data-table-td ">Kabi Pharmacia Ab</td><td class="patent-data-table-td ">Composition and method for prevention of adhesions between body tissues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5204537">US5204537</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 29, 1992</td><td class="patent-data-table-td patent-date-value">Apr 20, 1993</td><td class="patent-data-table-td ">Recognition Equipment Incorporated</td><td class="patent-data-table-td ">Thickness sensor comprising a leaf spring means, and a light sensor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5206023">US5206023</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 31, 1991</td><td class="patent-data-table-td patent-date-value">Apr 27, 1993</td><td class="patent-data-table-td ">Robert F. Shaw</td><td class="patent-data-table-td ">Method and compositions for the treatment and repair of defects or lesions in cartilage</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5217426">US5217426</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 14, 1991</td><td class="patent-data-table-td patent-date-value">Jun 8, 1993</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Combination disposable plastic blood receiving container and blood component centrifuge</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5217627">US5217627</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 6, 1991</td><td class="patent-data-table-td patent-date-value">Jun 8, 1993</td><td class="patent-data-table-td ">Pall Corporation</td><td class="patent-data-table-td ">System and method for processing biological fluid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5219328">US5219328</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 3, 1990</td><td class="patent-data-table-td patent-date-value">Jun 15, 1993</td><td class="patent-data-table-td ">Cryolife, Inc.</td><td class="patent-data-table-td ">Fibrin sealant delivery method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5226877">US5226877</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 23, 1989</td><td class="patent-data-table-td patent-date-value">Jul 13, 1993</td><td class="patent-data-table-td ">Epstein Gordon H</td><td class="patent-data-table-td ">Method and apparatus for preparing fibrinogen adhesive from whole blood</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5258126">US5258126</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 5, 1992</td><td class="patent-data-table-td patent-date-value">Nov 2, 1993</td><td class="patent-data-table-td ">Pall Corporation</td><td class="patent-data-table-td ">Method for obtaining platelets</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5260420">US5260420</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 24, 1992</td><td class="patent-data-table-td patent-date-value">Nov 9, 1993</td><td class="patent-data-table-td ">Centre Regional De Transfusion Sanguine De Lille</td><td class="patent-data-table-td ">Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5279825">US5279825</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 8, 1992</td><td class="patent-data-table-td patent-date-value">Jan 18, 1994</td><td class="patent-data-table-td ">Advance Biofactures Of Curacao, N.V.</td><td class="patent-data-table-td ">Adhesive consisting of fibrin and collagenase</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5281342">US5281342</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 19, 1992</td><td class="patent-data-table-td patent-date-value">Jan 25, 1994</td><td class="patent-data-table-td ">Fresenius Ag</td><td class="patent-data-table-td ">Method and apparatus for the separation of blood into its components</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5290552">US5290552</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 23, 1992</td><td class="patent-data-table-td patent-date-value">Mar 1, 1994</td><td class="patent-data-table-td ">Matrix Pharmaceutical, Inc./Project Hear</td><td class="patent-data-table-td ">Surgical adhesive material</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5290918">US5290918</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 23, 1993</td><td class="patent-data-table-td patent-date-value">Mar 1, 1994</td><td class="patent-data-table-td ">Haemacure Biotech Inc.</td><td class="patent-data-table-td ">Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5298171">US5298171</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 7, 1992</td><td class="patent-data-table-td patent-date-value">Mar 29, 1994</td><td class="patent-data-table-td ">Fresenius Ag</td><td class="patent-data-table-td ">Method and apparatus for separation of blood into its components</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5304372">US5304372</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 17, 1992</td><td class="patent-data-table-td patent-date-value">Apr 19, 1994</td><td class="patent-data-table-td ">Association Pour L&#39;essor De La Transfusion Sanguine Dans La Region Du Nord</td><td class="patent-data-table-td ">From blood</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5316674">US5316674</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 21, 1992</td><td class="patent-data-table-td patent-date-value">May 31, 1994</td><td class="patent-data-table-td ">Pall Corporation</td><td class="patent-data-table-td ">Filter to separarte red blood cells and platelets</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5321126">US5321126</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 17, 1992</td><td class="patent-data-table-td patent-date-value">Jun 14, 1994</td><td class="patent-data-table-td ">Harimex-Ligos B.V.</td><td class="patent-data-table-td ">Method of preparing a fibrinogen concentrate from blood plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5322620">US5322620</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 21, 1991</td><td class="patent-data-table-td patent-date-value">Jun 21, 1994</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Centrifugation system having an interface detection surface</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5330974">US5330974</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 1, 1993</td><td class="patent-data-table-td patent-date-value">Jul 19, 1994</td><td class="patent-data-table-td ">Fibratek, Inc.</td><td class="patent-data-table-td ">Therapeutic fibrinogen compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5370802">US5370802</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 22, 1992</td><td class="patent-data-table-td patent-date-value">Dec 6, 1994</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Enhanced yield platelet collection systems and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5376263">US5376263</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 2, 1993</td><td class="patent-data-table-td patent-date-value">Dec 27, 1994</td><td class="patent-data-table-td ">William F. McLaughlin</td><td class="patent-data-table-td ">Pump control apparatus for cellular filtration systems employing rotating microporous membranes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5395923">US5395923</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 23, 1993</td><td class="patent-data-table-td patent-date-value">Mar 7, 1995</td><td class="patent-data-table-td ">Haemacure-Biotech, Inc.</td><td class="patent-data-table-td ">Process for the obtention of a biological adhesive made of concentrated coagulation factors by &quot;salting-out&quot;</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5403272">US5403272</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 29, 1992</td><td class="patent-data-table-td patent-date-value">Apr 4, 1995</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Apparatus and methods for generating leukocyte free platelet concentrate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5405607">US5405607</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 12, 1993</td><td class="patent-data-table-td patent-date-value">Apr 11, 1995</td><td class="patent-data-table-td ">Epstein; Gordon H.</td><td class="patent-data-table-td ">Method for preparing fibrinogen adhesive from whole blood</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5411885">US5411885</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 17, 1993</td><td class="patent-data-table-td patent-date-value">May 2, 1995</td><td class="patent-data-table-td ">New York Blood Center, Inc.</td><td class="patent-data-table-td ">Methods for tissue embedding and tissue culturing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5417650">US5417650</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 18, 1993</td><td class="patent-data-table-td patent-date-value">May 23, 1995</td><td class="patent-data-table-td ">Advanced Haemotechnologies</td><td class="patent-data-table-td ">Apparatus for separating plasma and other wastes from blood</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5420250">US5420250</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 8, 1993</td><td class="patent-data-table-td patent-date-value">May 30, 1995</td><td class="patent-data-table-td ">Fibrin Corporation</td><td class="patent-data-table-td ">Phase transfer process for producing native plasma protein concentrates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5443481">US5443481</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 5, 1993</td><td class="patent-data-table-td patent-date-value">Aug 22, 1995</td><td class="patent-data-table-td ">Lee; Benjamin I.</td><td class="patent-data-table-td ">Methods and device for percutaneous sealing of arterial puncture sites</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5456693">US5456693</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 25, 1994</td><td class="patent-data-table-td patent-date-value">Oct 10, 1995</td><td class="patent-data-table-td ">Vitaphore Corporation</td><td class="patent-data-table-td ">Embolization plugs for blood vessels</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=kfFABAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DBR%26NR%3D9103724A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNEMGSXlDm0-TcecNiLiY_HA1DOTFA">BR9103724A</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/CN1074709A?cl=en">CN1074709A</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 26, 1992</td><td class="patent-data-table-td patent-date-value">Jul 28, 1993</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">fibrin ferment preparing process</td></tr><tr><td class="patent-data-table-td citation-patent"><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">DE56103C</td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE1443359A1?cl=en">DE1443359A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 19, 1962</td><td class="patent-data-table-td patent-date-value">Nov 14, 1968</td><td class="patent-data-table-td ">Pharmacia Ab</td><td class="patent-data-table-td ">Verfahren zur Herstellung von hochmolekularen hydrophilen Vernetzungsprodukten in Form von Gelkoernern</td></tr><tr><td class="patent-data-table-td citation-patent"><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">DE4202667A</td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0090997A2?cl=en">EP0090997A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 21, 1983</td><td class="patent-data-table-td patent-date-value">Oct 12, 1983</td><td class="patent-data-table-td ">Dr. Ruhland Nachf. GmbH</td><td class="patent-data-table-td ">Adhesive wound covering material comprising collagen</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0102773A2?cl=en">EP0102773A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 9, 1983</td><td class="patent-data-table-td patent-date-value">Mar 14, 1984</td><td class="patent-data-table-td ">Sony Corporation</td><td class="patent-data-table-td ">Delay circuit arrangements</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0109374A1?cl=en">EP0109374A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 10, 1983</td><td class="patent-data-table-td patent-date-value">May 23, 1984</td><td class="patent-data-table-td ">Antoon Soetens</td><td class="patent-data-table-td ">Apparatus for capturing solar energy on a roof or the like</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0253198B1?cl=en">EP0253198B1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 30, 1987</td><td class="patent-data-table-td patent-date-value">Sep 26, 1990</td><td class="patent-data-table-td ">BEHRINGWERKE Aktiengesellschaft</td><td class="patent-data-table-td ">Single-component tissue adhesive and method for producing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0534178A2?cl=en">EP0534178A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 2, 1992</td><td class="patent-data-table-td patent-date-value">Mar 31, 1993</td><td class="patent-data-table-td ">Opperbas Holding B.V.</td><td class="patent-data-table-td ">Improved tissue glue prepared by using cryoprecipitate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0592242A1?cl=en">EP0592242A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 8, 1993</td><td class="patent-data-table-td patent-date-value">Apr 13, 1994</td><td class="patent-data-table-td ">E.R. SQUIBB &amp;amp; SONS, INC.</td><td class="patent-data-table-td ">Fibrin sealant compositions and method for utilizing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=kfFABAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DGB%26NR%3D854715A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNF0Oi0eTPiQwAKs1iBG7Xe98BM7kQ">GB854715A</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1988002259A1?cl=en">WO1988002259A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 2, 1987</td><td class="patent-data-table-td patent-date-value">Apr 7, 1988</td><td class="patent-data-table-td ">Weis Fogh Ulla Sivertsen</td><td class="patent-data-table-td ">A method and an apparatus for preparing tissue repair promoting substances</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1990010031A1?cl=en">WO1990010031A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 21, 1990</td><td class="patent-data-table-td patent-date-value">Sep 7, 1990</td><td class="patent-data-table-td ">Pharmacia Ab</td><td class="patent-data-table-td ">Composition and method for prevention of adhesions between body tissues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1992022312A1?cl=en">WO1992022312A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 17, 1992</td><td class="patent-data-table-td patent-date-value">Dec 23, 1992</td><td class="patent-data-table-td ">Jonas Wadstroem</td><td class="patent-data-table-td ">Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1993005067A1?cl=en">WO1993005067A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 4, 1992</td><td class="patent-data-table-td patent-date-value">Mar 18, 1993</td><td class="patent-data-table-td ">Baxter Int</td><td class="patent-data-table-td ">Topical fibrinogen complex</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Anesthesiology, vol. 81, No. 4, pp. 1074 1077, Oct. 1994, Hiromasa Mitsuhata, MD, et al., An Anaphylactic Reaction to Topical Fibrin Glue .</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Anesthesiology, vol. 81, No. 4, pp. 1074-1077, Oct. 1994, Hiromasa Mitsuhata, MD, et al., "<a href='http://scholar.google.com/scholar?q="An+Anaphylactic+Reaction+to+Topical+Fibrin+Glue"'>An Anaphylactic Reaction to Topical Fibrin Glue</a>".</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ann Thorac Surg, vol. 53, pp. 530 531, 1992, Mehmet C. Oz, MD, et al., Autologous Fibrin GLue From Intraoperatively Collected Platelet Rich Plasma .</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ann Thorac Surg, vol. 53, pp. 530-531, 1992, Mehmet C. Oz, MD, et al., "<a href='http://scholar.google.com/scholar?q="Autologous+Fibrin+GLue+From+Intraoperatively+Collected+Platelet-Rich+Plasma"'>Autologous Fibrin GLue From Intraoperatively Collected Platelet-Rich Plasma</a>".</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ann Thorac Surg, vol. 56, pp. 387 389, 1993, Robert L. Quigley, MD. et al., Intraoperative Procurement of Autologous Fibrin Glue .</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ann Thorac Surg, vol. 56, pp. 387-389, 1993, Robert L. Quigley, MD. et al., "<a href='http://scholar.google.com/scholar?q="Intraoperative+Procurement+of+Autologous+Fibrin+Glue"'>Intraoperative Procurement of Autologous Fibrin Glue</a>".</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Biopolymers, vol. 27, pp. 763 774, 1988, Gerald Marx; Mechanism of Fibrin Coagulation Based on Selective, Cation Driven, Protofibril Association .</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Biopolymers, vol. 27, pp. 763-774, 1988, Gerald Marx; "<a href='http://scholar.google.com/scholar?q="Mechanism+of+Fibrin+Coagulation+Based+on+Selective%2C+Cation-Driven%2C+Protofibril+Association"'>Mechanism of Fibrin Coagulation Based on Selective, Cation-Driven, Protofibril Association</a>".</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Drug Intelligence and Clinical Pharmacy, vol. 22, pp. 946 952, Dec. 1988, Dennis F. Thompson, et al., Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects As A Topical Hemostat .</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Drug Intelligence and Clinical Pharmacy, vol. 22, pp. 946-952, Dec. 1988, Dennis F. Thompson, et al., "<a href='http://scholar.google.com/scholar?q="Fibrin+Glue%3A+A+Review+of+Its+Preparation%2C+Efficacy%2C+and+Adverse+Effects+As+A+Topical+Hemostat"'>Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects As A Topical Hemostat</a>".</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Journal of Biomaterials Applications, vol. 7, pp. 309 353, Apr. 1993, David H. Sierra, Fibrin Sealant Adhesive Systems: A Review of Their Chemistry, Material Properties and Clinical Applications .</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Biomaterials Applications, vol. 7, pp. 309-353, Apr. 1993, David H. Sierra, "<a href='http://scholar.google.com/scholar?q="Fibrin+Sealant+Adhesive+Systems%3A+A+Review+of+Their+Chemistry%2C+Material+Properties+and+Clinical+Applications"'>Fibrin Sealant Adhesive Systems: A Review of Their Chemistry, Material Properties and Clinical Applications</a>".</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Journal of Oral Maxillofacial Surgery, vol. 43, pp. 605 611, 1985, Helene Matras, MD, Fibrin Seal: The State of The Art .</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of Oral Maxillofacial Surgery, vol. 43, pp. 605-611, 1985, Helene Matras, MD, "<a href='http://scholar.google.com/scholar?q="Fibrin+Seal%3A+The+State+of+The+Art"'>Fibrin Seal: The State of The Art</a>".</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Laryngoscope, vol. 95, pp. 1074 1076, Sep. 1985, Karl H. Siedentop, MD, et al., Autologous Fibrin Tissue Adhesive .</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Laryngoscope, vol. 95, pp. 1074-1076, Sep. 1985, Karl H. Siedentop, MD, et al., "<a href='http://scholar.google.com/scholar?q="Autologous+Fibrin+Tissue+Adhesive"'>Autologous Fibrin Tissue Adhesive</a>".</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Laryngoscope, vol. 96, pp. 1062 1064, Oct. 1986, Karl H. Siedentop, MD, et al., Extended Experimental and Preliminary Surgical Findings with Autologous Fibrin Tissue Adhesive Made From Patient s Own Blood .</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Laryngoscope, vol. 96, pp. 1062-1064, Oct. 1986, Karl H. Siedentop, MD, et al., "<a href='http://scholar.google.com/scholar?q="Extended+Experimental+and+Preliminary+Surgical+Findings+with+Autologous+Fibrin+Tissue+Adhesive+Made+From+Patient%27s+Own+Blood"'>Extended Experimental and Preliminary Surgical Findings with Autologous Fibrin Tissue Adhesive Made From Patient's Own Blood</a>".</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Laryngoscope, vol. 99, pp. 974 976, Sep. 1989, Kyosti Laitakari, MD, et al., Autologous and Homologous Fibrinogen Sealants: Adhesive Strength .</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Laryngoscope, vol. 99, pp. 974-976, Sep. 1989, Kyosti Laitakari, MD, et al., "<a href='http://scholar.google.com/scholar?q="Autologous+and+Homologous+Fibrinogen+Sealants%3A+Adhesive+Strength"'>Autologous and Homologous Fibrinogen Sealants: Adhesive Strength</a>".</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Otolaryngologic Clinics of North America, vol. 27, No. 1, pp. 203 209, Feb. 1994, Dean M. Toriumi, MD, et al., Surgical Tissue Adhesives in Otolaryngology Head and Neck Surgery .</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Otolaryngologic Clinics of North America, vol. 27, No. 1, pp. 203-209, Feb. 1994, Dean M. Toriumi, MD, et al., "<a href='http://scholar.google.com/scholar?q="Surgical+Tissue+Adhesives+in+Otolaryngology-Head+and+Neck+Surgery"'>Surgical Tissue Adhesives in Otolaryngology-Head and Neck Surgery</a>".</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">The American Journal of Surgery, vol. 168, pp. 120 122, Aug. 1994, Roy L. Tawes, Jr. MD, et al., Autologous Fibrin Glue: The Last Step in Operative Hemostasis .</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The American Journal of Surgery, vol. 168, pp. 120-122, Aug. 1994, Roy L. Tawes, Jr. MD, et al., "<a href='http://scholar.google.com/scholar?q="Autologous+Fibrin+Glue%3A+The+Last+Step+in+Operative+Hemostasis"'>Autologous Fibrin Glue: The Last Step in Operative Hemostasis</a>".</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">The American Surgeon, vol. 55, pp. 166 168, Mar. 1989, William D. Spotnitz, MD, et al., Successful Use of Fibrin Glue During 2 Years of Surgery At A University Medical Center .</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">The American Surgeon, vol. 55, pp. 166-168, Mar. 1989, William D. Spotnitz, MD, et al., "<a href='http://scholar.google.com/scholar?q="Successful+Use+of+Fibrin+Glue+During+2+Years+of+Surgery+At+A+University+Medical+Center"'>Successful Use of Fibrin Glue During 2 Years of Surgery At A University Medical Center</a>".</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Transfusion, vol. 30, No. 8, pp. 741 747, 1990, J. W. Gibble, et al., Fibrin Glue: The Perfect Operative Sealant .</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Transfusion, vol. 30, No. 8, pp. 741-747, 1990, J. W. Gibble, et al., "<a href='http://scholar.google.com/scholar?q="Fibrin+Glue%3A+The+Perfect+Operative+Sealant%3F"'>Fibrin Glue: The Perfect Operative Sealant?</a>".</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5733545">US5733545</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 27, 1996</td><td class="patent-data-table-td patent-date-value">Mar 31, 1998</td><td class="patent-data-table-td ">Quantic Biomedical Partners</td><td class="patent-data-table-td ">Mixture containing plasma, fibrinogen, platelets and white cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5795489">US5795489</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 8, 1996</td><td class="patent-data-table-td patent-date-value">Aug 18, 1998</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Separation of particles from liquid, rotation and filtration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5887755">US5887755</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 21, 1997</td><td class="patent-data-table-td patent-date-value">Mar 30, 1999</td><td class="patent-data-table-td ">Quantic Biomedical Partners</td><td class="patent-data-table-td ">Wound sealant preparation and application device and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5899873">US5899873</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 24, 1997</td><td class="patent-data-table-td patent-date-value">May 4, 1999</td><td class="patent-data-table-td ">Quest Medical, Inc.</td><td class="patent-data-table-td ">Biological fluid delivery system</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6010627">US6010627</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 19, 1996</td><td class="patent-data-table-td patent-date-value">Jan 4, 2000</td><td class="patent-data-table-td ">Quantic Biomedical Partners</td><td class="patent-data-table-td ">Device for concentrating plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6083383">US6083383</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 25, 1998</td><td class="patent-data-table-td patent-date-value">Jul 4, 2000</td><td class="patent-data-table-td ">Huang; Xun Yang</td><td class="patent-data-table-td ">Sterile and closed system</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6159232">US6159232</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 15, 1998</td><td class="patent-data-table-td patent-date-value">Dec 12, 2000</td><td class="patent-data-table-td ">Closys Corporation</td><td class="patent-data-table-td ">Clotting cascade initiating apparatus and methods of use and methods of closing wounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6268483">US6268483</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 9, 1998</td><td class="patent-data-table-td patent-date-value">Jul 31, 2001</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Taking blood sample from patient, harvesting solution wich contains fibrin monomer, prothrombin, and factor xiii in certain concentrations, then forming fibrin polymer; for use in same patient</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6274090">US6274090</a></td><td class="patent-data-table-td patent-date-value">Aug 5, 1998</td><td class="patent-data-table-td patent-date-value">Aug 14, 2001</td><td class="patent-data-table-td ">Thermogenesis Corp.</td><td class="patent-data-table-td ">Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6303112">US6303112</a></td><td class="patent-data-table-td patent-date-value">Nov 23, 1999</td><td class="patent-data-table-td patent-date-value">Oct 16, 2001</td><td class="patent-data-table-td ">Cytomedix Inc</td><td class="patent-data-table-td ">Enriched platelet wound healant</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6331172">US6331172</a></td><td class="patent-data-table-td patent-date-value">Apr 14, 1997</td><td class="patent-data-table-td patent-date-value">Dec 18, 2001</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Applicator for dispensing measured quantities with use of controlled suction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6342157">US6342157</a></td><td class="patent-data-table-td patent-date-value">Nov 19, 1999</td><td class="patent-data-table-td patent-date-value">Jan 29, 2002</td><td class="patent-data-table-td ">Interpore Orthopedics, Inc.</td><td class="patent-data-table-td ">Device and method for concentrating plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6368298">US6368298</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 24, 1998</td><td class="patent-data-table-td patent-date-value">Apr 9, 2002</td><td class="patent-data-table-td ">Roberto Beretta</td><td class="patent-data-table-td ">Preparing autologous fibrin glue</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6444228">US6444228</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 20, 1998</td><td class="patent-data-table-td patent-date-value">Sep 3, 2002</td><td class="patent-data-table-td ">Medtronic, Inc.</td><td class="patent-data-table-td ">Autologous fibrin sealant and method for making the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6461361">US6461361</a></td><td class="patent-data-table-td patent-date-value">Apr 30, 1999</td><td class="patent-data-table-td patent-date-value">Oct 8, 2002</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Gas-driven spraying of mixed sealant agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6464624">US6464624</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 12, 2001</td><td class="patent-data-table-td patent-date-value">Oct 15, 2002</td><td class="patent-data-table-td ">Haemonetics Corporation</td><td class="patent-data-table-td ">Blood processing method and apparatus using a centrifugation bowl with filter core</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6472162">US6472162</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 4, 1999</td><td class="patent-data-table-td patent-date-value">Oct 29, 2002</td><td class="patent-data-table-td ">Thermogenesis Corp.</td><td class="patent-data-table-td ">Obtaining blood from a patient, sequestering plasma, adding ethanol in a concentration fo 8-20% to prepare a solution containing prothrombin, converting to thrombin, filtering and applying to a patient</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6475183">US6475183</a></td><td class="patent-data-table-td patent-date-value">May 7, 1999</td><td class="patent-data-table-td patent-date-value">Nov 5, 2002</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Direct dual filling device for sealing agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6478808">US6478808</a></td><td class="patent-data-table-td patent-date-value">Dec 7, 2000</td><td class="patent-data-table-td patent-date-value">Nov 12, 2002</td><td class="patent-data-table-td ">Closys Corporation</td><td class="patent-data-table-td ">Clotting cascade initiating apparatus and methods of use and methods of closing wounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6482223">US6482223</a></td><td class="patent-data-table-td patent-date-value">Jun 1, 2000</td><td class="patent-data-table-td patent-date-value">Nov 19, 2002</td><td class="patent-data-table-td ">Closys Corporation</td><td class="patent-data-table-td ">Clotting cascade initiating apparatus and methods of use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6488650">US6488650</a></td><td class="patent-data-table-td patent-date-value">Dec 8, 1999</td><td class="patent-data-table-td patent-date-value">Dec 3, 2002</td><td class="patent-data-table-td ">Baxter International, Inc.</td><td class="patent-data-table-td ">Direct dual filling device for sealing agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6575940">US6575940</a></td><td class="patent-data-table-td patent-date-value">May 20, 1999</td><td class="patent-data-table-td patent-date-value">Jun 10, 2003</td><td class="patent-data-table-td ">Baxter Healthcare Corporation</td><td class="patent-data-table-td ">Sealant applicator and method employing impulse clearing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6596180">US6596180</a></td><td class="patent-data-table-td patent-date-value">Apr 9, 2001</td><td class="patent-data-table-td patent-date-value">Jul 22, 2003</td><td class="patent-data-table-td ">Medtronic, Inc.</td><td class="patent-data-table-td ">System and method for the production of autologous platelet gel</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6629919">US6629919</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 18, 2001</td><td class="patent-data-table-td patent-date-value">Oct 7, 2003</td><td class="patent-data-table-td ">Haemonetics Corporation</td><td class="patent-data-table-td ">Core for blood processing apparatus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6644365">US6644365</a></td><td class="patent-data-table-td patent-date-value">Apr 19, 2002</td><td class="patent-data-table-td patent-date-value">Nov 11, 2003</td><td class="patent-data-table-td ">Baxter International, Inc.</td><td class="patent-data-table-td ">Tilting direct dual filling device</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6716187">US6716187</a></td><td class="patent-data-table-td patent-date-value">Jul 7, 2000</td><td class="patent-data-table-td patent-date-value">Apr 6, 2004</td><td class="patent-data-table-td ">Implant Innovations, Inc.</td><td class="patent-data-table-td ">Movable plunger mounted within blood container for expressing fractions separated during centrifugation; single-use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6719901">US6719901</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 9, 2001</td><td class="patent-data-table-td patent-date-value">Apr 13, 2004</td><td class="patent-data-table-td ">Medtronic, Inc.</td><td class="patent-data-table-td ">System for the production of an autologous thrombin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6733472">US6733472</a></td><td class="patent-data-table-td patent-date-value">Aug 18, 1999</td><td class="patent-data-table-td patent-date-value">May 11, 2004</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Sealant applicator tip and application method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6770050">US6770050</a></td><td class="patent-data-table-td patent-date-value">Mar 27, 2001</td><td class="patent-data-table-td patent-date-value">Aug 3, 2004</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Multipurpose fluid applicator and method, with surgical uses</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6808638">US6808638</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 21, 1999</td><td class="patent-data-table-td patent-date-value">Oct 26, 2004</td><td class="patent-data-table-td ">Throwleigh Technologies, L.L.C.</td><td class="patent-data-table-td ">Methods and apparatus for processing temperature sensitive materials</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6811777">US6811777</a></td><td class="patent-data-table-td patent-date-value">Apr 11, 2003</td><td class="patent-data-table-td patent-date-value">Nov 2, 2004</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Compositions and minimally invasive methods for treating incomplete connective tissue repair</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6830762">US6830762</a></td><td class="patent-data-table-td patent-date-value">Jun 18, 2002</td><td class="patent-data-table-td patent-date-value">Dec 14, 2004</td><td class="patent-data-table-td ">Medtronic, Inc.</td><td class="patent-data-table-td ">Autologous fibrin sealant and method for making the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6841170">US6841170</a></td><td class="patent-data-table-td patent-date-value">Dec 13, 2000</td><td class="patent-data-table-td patent-date-value">Jan 11, 2005</td><td class="patent-data-table-td ">Maria Cristina Sacchi</td><td class="patent-data-table-td ">Using as the activator batroxobin in place of thrombin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6899813">US6899813</a></td><td class="patent-data-table-td patent-date-value">Dec 17, 2003</td><td class="patent-data-table-td patent-date-value">May 31, 2005</td><td class="patent-data-table-td ">Medtronic, Inc.</td><td class="patent-data-table-td ">Method for the production of a blood component composition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6905612">US6905612</a></td><td class="patent-data-table-td patent-date-value">Mar 21, 2003</td><td class="patent-data-table-td patent-date-value">Jun 14, 2005</td><td class="patent-data-table-td ">Hanuman Llc</td><td class="patent-data-table-td ">Plasma concentrate apparatus and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6926695">US6926695</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2003</td><td class="patent-data-table-td patent-date-value">Aug 9, 2005</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Sealant applicator and method employing impulse clearing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6979307">US6979307</a></td><td class="patent-data-table-td patent-date-value">Jan 15, 2002</td><td class="patent-data-table-td patent-date-value">Dec 27, 2005</td><td class="patent-data-table-td ">Cascade Medical Enterprises Llc</td><td class="patent-data-table-td ">Systems and methods for preparing autologous fibrin glue</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6982038">US6982038</a></td><td class="patent-data-table-td patent-date-value">Jan 10, 2003</td><td class="patent-data-table-td patent-date-value">Jan 3, 2006</td><td class="patent-data-table-td ">Medtronic, Inc.</td><td class="patent-data-table-td ">Centrifuge system utilizing disposable components and automated processing of blood to collect platelet rich plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6989022">US6989022</a></td><td class="patent-data-table-td patent-date-value">Nov 8, 2002</td><td class="patent-data-table-td patent-date-value">Jan 24, 2006</td><td class="patent-data-table-td ">Closys Corporation</td><td class="patent-data-table-td ">Clotting cascade initiating apparatus and methods of use and methods of closing wounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7025755">US7025755</a></td><td class="patent-data-table-td patent-date-value">May 31, 2002</td><td class="patent-data-table-td patent-date-value">Apr 11, 2006</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Medical suctioning apparatus and methods of use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7056722">US7056722</a></td><td class="patent-data-table-td patent-date-value">Nov 10, 2000</td><td class="patent-data-table-td patent-date-value">Jun 6, 2006</td><td class="patent-data-table-td ">Thermogenesis Corp.</td><td class="patent-data-table-td ">Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7081103">US7081103</a></td><td class="patent-data-table-td patent-date-value">Nov 4, 2002</td><td class="patent-data-table-td patent-date-value">Jul 25, 2006</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Direct dual filling device for sealing agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7166231">US7166231</a></td><td class="patent-data-table-td patent-date-value">Jan 9, 2003</td><td class="patent-data-table-td patent-date-value">Jan 23, 2007</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Red blood cell separation method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7179391">US7179391</a></td><td class="patent-data-table-td patent-date-value">May 23, 2003</td><td class="patent-data-table-td patent-date-value">Feb 20, 2007</td><td class="patent-data-table-td ">Biomet Manufacturing Corp.</td><td class="patent-data-table-td ">Forming two fraction by centrifuging the multi-component fluid disposed in the container, containing the first fraction in a collection area of a first piston with a selected volume of the secong fraction and withdrawing it from the container; kits; whole blood sample, adipose tissue, or a bone marrows</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7207969">US7207969</a></td><td class="patent-data-table-td patent-date-value">Dec 2, 2002</td><td class="patent-data-table-td patent-date-value">Apr 24, 2007</td><td class="patent-data-table-td ">Baxter International Inc.</td><td class="patent-data-table-td ">Direct dual filling device for sealing agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7223346">US7223346</a></td><td class="patent-data-table-td patent-date-value">Apr 18, 2005</td><td class="patent-data-table-td patent-date-value">May 29, 2007</td><td class="patent-data-table-td ">Hanuman Llc</td><td class="patent-data-table-td ">A centrifugal spin-separator with a float in the cavity that has a density between the erythrocytes and plasma and moves through the sedimenting erythrocytes during centrifugation and releases trapped platelets</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7252758">US7252758</a></td><td class="patent-data-table-td patent-date-value">Nov 10, 2005</td><td class="patent-data-table-td patent-date-value">Aug 7, 2007</td><td class="patent-data-table-td ">Medtronic, Inc.</td><td class="patent-data-table-td ">Centrifuge system utilizing disposable components and automated processing of blood to collect platelet rich plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7297272">US7297272</a></td><td class="patent-data-table-td patent-date-value">Apr 19, 2004</td><td class="patent-data-table-td patent-date-value">Nov 20, 2007</td><td class="patent-data-table-td ">Fenwal, Inc.</td><td class="patent-data-table-td ">Separation apparatus and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7306555">US7306555</a></td><td class="patent-data-table-td patent-date-value">Sep 8, 2006</td><td class="patent-data-table-td patent-date-value">Dec 11, 2007</td><td class="patent-data-table-td ">Medtronic, Inc.</td><td class="patent-data-table-td ">Centrifuge system utilizing disposable components and automated processing of blood to collect platelet rich plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7314617">US7314617</a></td><td class="patent-data-table-td patent-date-value">Sep 15, 2004</td><td class="patent-data-table-td patent-date-value">Jan 1, 2008</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Platelet rich plasma, no exogenous activator; sodium bicarbonate buffer, citrate dextrose anticoagulant</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7413652">US7413652</a></td><td class="patent-data-table-td patent-date-value">Apr 26, 2005</td><td class="patent-data-table-td patent-date-value">Aug 19, 2008</td><td class="patent-data-table-td ">Arteriocyte Medical Systems, Inc.</td><td class="patent-data-table-td ">Method for the production of a blood component composition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7452344">US7452344</a></td><td class="patent-data-table-td patent-date-value">Feb 23, 2004</td><td class="patent-data-table-td patent-date-value">Nov 18, 2008</td><td class="patent-data-table-td ">Biomet 3I, Llc</td><td class="patent-data-table-td ">Platelet concentration syringe kit</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7462268">US7462268</a></td><td class="patent-data-table-td patent-date-value">Aug 16, 2005</td><td class="patent-data-table-td patent-date-value">Dec 9, 2008</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Particle/cell separation device and compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7553413">US7553413</a></td><td class="patent-data-table-td patent-date-value">Jan 30, 2006</td><td class="patent-data-table-td patent-date-value">Jun 30, 2009</td><td class="patent-data-table-td ">Hanuman Llc</td><td class="patent-data-table-td ">Plasma concentrator device</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7608258">US7608258</a></td><td class="patent-data-table-td patent-date-value">Mar 22, 2005</td><td class="patent-data-table-td patent-date-value">Oct 27, 2009</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Anticoagulant, a disposable separating tube in a centrifugation device for isolating platelet fractions from the blood, a pH adjusting agent, a platelet delivery device for applying the buffered platelet-rich plasma to tissue with a compromised blood supply to vascularize the tissue</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7678780">US7678780</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 2004</td><td class="patent-data-table-td patent-date-value">Mar 16, 2010</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Method of treating cancer using platelet releasate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7694828">US7694828</a></td><td class="patent-data-table-td patent-date-value">Apr 27, 2005</td><td class="patent-data-table-td patent-date-value">Apr 13, 2010</td><td class="patent-data-table-td ">Biomet Manufacturing Corp.</td><td class="patent-data-table-td ">Method and apparatus for producing autologous clotting components</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7745106">US7745106</a></td><td class="patent-data-table-td patent-date-value">Jun 26, 2003</td><td class="patent-data-table-td patent-date-value">Jun 29, 2010</td><td class="patent-data-table-td ">Cascade Medical Enterprises, Llc</td><td class="patent-data-table-td ">Methods and devices for separating liquid components</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7789245">US7789245</a></td><td class="patent-data-table-td patent-date-value">Aug 3, 2009</td><td class="patent-data-table-td patent-date-value">Sep 7, 2010</td><td class="patent-data-table-td ">Fenwal, Inc.</td><td class="patent-data-table-td ">Blood separation chamber</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7806845">US7806845</a></td><td class="patent-data-table-td patent-date-value">Apr 23, 2003</td><td class="patent-data-table-td patent-date-value">Oct 5, 2010</td><td class="patent-data-table-td ">Biomet Biologics, Llc</td><td class="patent-data-table-td ">Blood separation and concentration system</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7811607">US7811607</a></td><td class="patent-data-table-td patent-date-value">Dec 3, 2004</td><td class="patent-data-table-td patent-date-value">Oct 12, 2010</td><td class="patent-data-table-td ">Arteriocyte Medical Systems, Inc.</td><td class="patent-data-table-td ">Autologous fibrin sealant and method for making the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7837708">US7837708</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 22, 2005</td><td class="patent-data-table-td patent-date-value">Nov 23, 2010</td><td class="patent-data-table-td ">Arthrex, Inc.</td><td class="patent-data-table-td ">Placing a length of suture into a sterile container;obtaining an autogenous blood component by centrifuging the patient&#39;s blood,dding an anticoagulant to keep the blood component in suspension and then adding to the container where the suture soaks up the autogenous blood component; surgery</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7838039">US7838039</a></td><td class="patent-data-table-td patent-date-value">Jan 27, 2005</td><td class="patent-data-table-td patent-date-value">Nov 23, 2010</td><td class="patent-data-table-td ">Arteriocyte Medical Systems, Inc.</td><td class="patent-data-table-td ">preparing a completely autologous bioadhesive sealant composition; all the blood components come from the patient to whom the sealant will be used</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7867159">US7867159</a></td><td class="patent-data-table-td patent-date-value">Jun 4, 2007</td><td class="patent-data-table-td patent-date-value">Jan 11, 2011</td><td class="patent-data-table-td ">Arteriocyte Medical Systems, Inc.</td><td class="patent-data-table-td ">Centrifuge system utilizing disposable components and automated processing of blood to collect platelet rich plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7901344">US7901344</a></td><td class="patent-data-table-td patent-date-value">May 9, 2008</td><td class="patent-data-table-td patent-date-value">Mar 8, 2011</td><td class="patent-data-table-td ">Biomet Biologics, Llc</td><td class="patent-data-table-td ">Methods of reducing surgical complications in cancer patients</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7901584">US7901584</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 2009</td><td class="patent-data-table-td patent-date-value">Mar 8, 2011</td><td class="patent-data-table-td ">Hanuman, Llc</td><td class="patent-data-table-td ">Plasma concentration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7918350">US7918350</a></td><td class="patent-data-table-td patent-date-value">Mar 6, 2009</td><td class="patent-data-table-td patent-date-value">Apr 5, 2011</td><td class="patent-data-table-td ">Fenwal, Inc.</td><td class="patent-data-table-td ">Separation apparatus and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7934603">US7934603</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 2, 2005</td><td class="patent-data-table-td patent-date-value">May 3, 2011</td><td class="patent-data-table-td ">Arteriocyte Medical Systems, Inc.</td><td class="patent-data-table-td ">Autologous platelet gel spray delivery system</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8017157">US8017157</a></td><td class="patent-data-table-td patent-date-value">Dec 12, 2006</td><td class="patent-data-table-td patent-date-value">Sep 13, 2011</td><td class="patent-data-table-td ">Osiris Therapeutics, Inc.</td><td class="patent-data-table-td ">Method of treating a wound with acidified plasma or serum</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8034014">US8034014</a></td><td class="patent-data-table-td patent-date-value">Mar 6, 2007</td><td class="patent-data-table-td patent-date-value">Oct 11, 2011</td><td class="patent-data-table-td ">Biomet Biologics, Llc</td><td class="patent-data-table-td ">Promoting angiogenesis by administering platelet-rich plasma to a site and stimulating the site with an electromagnetic field; use in treating coronary artery disease, stroke, delayed wound healing, chronic wounds, peripheral vascular disease, ischemia, chronic tendonosis, tissue breakdown</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8075468">US8075468</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2009</td><td class="patent-data-table-td patent-date-value">Dec 13, 2011</td><td class="patent-data-table-td ">Fenwal, Inc.</td><td class="patent-data-table-td ">Systems and methods for mid-processing calculation of blood composition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8088371">US8088371</a></td><td class="patent-data-table-td patent-date-value">Jun 17, 2008</td><td class="patent-data-table-td patent-date-value">Jan 3, 2012</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Deliver platelet rich plasma, sodium bicarbonate, calcium gluconate, choline chloride buffers, thrombin, collagen, epinephrine releasate, via catheter; coat suture, stent, screw, plate implants with plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8101077">US8101077</a></td><td class="patent-data-table-td patent-date-value">Aug 25, 2006</td><td class="patent-data-table-td patent-date-value">Jan 24, 2012</td><td class="patent-data-table-td ">Sivaprasad Sukavaneshvar</td><td class="patent-data-table-td ">Device for separating platelets from fluid suspensions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8124075">US8124075</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 14, 2005</td><td class="patent-data-table-td patent-date-value">Feb 28, 2012</td><td class="patent-data-table-td ">Spinal Restoration, Inc.</td><td class="patent-data-table-td ">treating a human spinal disc with defect by injecting into the disc a mixture comprises supplement drug and autologous fibrinogen and a snake venom to change fibrinogen to fibrin biosealants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8142993">US8142993</a></td><td class="patent-data-table-td patent-date-value">Dec 16, 2011</td><td class="patent-data-table-td patent-date-value">Mar 27, 2012</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Method of preparing neutrophil-depleted platelet-rich plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8163277">US8163277</a></td><td class="patent-data-table-td patent-date-value">Jul 27, 2006</td><td class="patent-data-table-td patent-date-value">Apr 24, 2012</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Deliver platelet rich plasma, sodium bicarbonate, calcium gluconate, choline chloride buffers, thrombin, collagen, epinephrine releasate, via catheter; stent implants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8163549">US8163549</a></td><td class="patent-data-table-td patent-date-value">Dec 20, 2006</td><td class="patent-data-table-td patent-date-value">Apr 24, 2012</td><td class="patent-data-table-td ">Zimmer Orthobiologics, Inc.</td><td class="patent-data-table-td ">Plurality of isolated viable tissue particles comprising cells having 80% viability and their associated extracellular proteins, polysaccharides, proteoglycans, each particle sized to have at least one dimension less than 60 mu m; repairing orthopedic tissue defects</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8262608">US8262608</a></td><td class="patent-data-table-td patent-date-value">Jan 25, 2008</td><td class="patent-data-table-td patent-date-value">Sep 11, 2012</td><td class="patent-data-table-td ">Hyperbranch Medical Technology, Inc.</td><td class="patent-data-table-td ">Applicators for multiple component formulations and the like, and methods of use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8263223">US8263223</a></td><td class="patent-data-table-td patent-date-value">Mar 14, 2003</td><td class="patent-data-table-td patent-date-value">Sep 11, 2012</td><td class="patent-data-table-td ">Biointeractions, Ltd.</td><td class="patent-data-table-td ">Coated surfaces for immobilizing negatively charged anticoagulating agents from blood fluid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8293530">US8293530</a></td><td class="patent-data-table-td patent-date-value">Oct 17, 2007</td><td class="patent-data-table-td patent-date-value">Oct 23, 2012</td><td class="patent-data-table-td ">Carnegie Mellon University</td><td class="patent-data-table-td ">Method and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8303993">US8303993</a></td><td class="patent-data-table-td patent-date-value">Jun 23, 2005</td><td class="patent-data-table-td patent-date-value">Nov 6, 2012</td><td class="patent-data-table-td ">Ateriocyte Medical Systems, Inc.</td><td class="patent-data-table-td ">preparing a completely autologous bioadhesive sealant composition; all the blood components come from the patient to whom the sealant will be used</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8308340">US8308340</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 2005</td><td class="patent-data-table-td patent-date-value">Nov 13, 2012</td><td class="patent-data-table-td ">Smith &amp; Nephew, Inc.</td><td class="patent-data-table-td ">Composite mixer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8317672">US8317672</a></td><td class="patent-data-table-td patent-date-value">Nov 19, 2010</td><td class="patent-data-table-td patent-date-value">Nov 27, 2012</td><td class="patent-data-table-td ">Kensey Nash Corporation</td><td class="patent-data-table-td ">Centrifuge method and apparatus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8343084">US8343084</a></td><td class="patent-data-table-td patent-date-value">Oct 29, 2010</td><td class="patent-data-table-td patent-date-value">Jan 1, 2013</td><td class="patent-data-table-td ">Closys Corporation</td><td class="patent-data-table-td ">Clotting cascade initiating apparatus and methods of use and methods of closing wounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8361005">US8361005</a></td><td class="patent-data-table-td patent-date-value">Sep 2, 2010</td><td class="patent-data-table-td patent-date-value">Jan 29, 2013</td><td class="patent-data-table-td ">Biomet Biologics, Llc</td><td class="patent-data-table-td ">Blood separation and concentration system</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8394006">US8394006</a></td><td class="patent-data-table-td patent-date-value">Apr 13, 2012</td><td class="patent-data-table-td patent-date-value">Mar 12, 2013</td><td class="patent-data-table-td ">Kensey Nash Corporation</td><td class="patent-data-table-td ">Centrifuge</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8394072">US8394072</a></td><td class="patent-data-table-td patent-date-value">Oct 5, 2009</td><td class="patent-data-table-td patent-date-value">Mar 12, 2013</td><td class="patent-data-table-td ">Spinal Restoration, Inc.</td><td class="patent-data-table-td ">Injection of fibrin sealant including an anesthetic in spinal applications</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8403895">US8403895</a></td><td class="patent-data-table-td patent-date-value">Oct 5, 2009</td><td class="patent-data-table-td patent-date-value">Mar 26, 2013</td><td class="patent-data-table-td ">Spinal Restoration, Inc.</td><td class="patent-data-table-td ">Injection of fibrin sealant including an anesthetic in spinal applications</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8440459">US8440459</a></td><td class="patent-data-table-td patent-date-value">Oct 8, 2009</td><td class="patent-data-table-td patent-date-value">May 14, 2013</td><td class="patent-data-table-td ">Allan Kumar Mishra</td><td class="patent-data-table-td ">Platelet rich plasma formulations for cardiac treatments</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8444969">US8444969</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2011</td><td class="patent-data-table-td patent-date-value">May 21, 2013</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Neutrophil-depleted platelet rich plasma formulations for cardiac treatments</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8469871">US8469871</a></td><td class="patent-data-table-td patent-date-value">Aug 12, 2011</td><td class="patent-data-table-td patent-date-value">Jun 25, 2013</td><td class="patent-data-table-td ">Kensey Nash Corporation</td><td class="patent-data-table-td ">Centrifuge</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8480757">US8480757</a></td><td class="patent-data-table-td patent-date-value">Aug 28, 2006</td><td class="patent-data-table-td patent-date-value">Jul 9, 2013</td><td class="patent-data-table-td ">Zimmer, Inc.</td><td class="patent-data-table-td ">Implants and methods for repair, replacement and treatment of disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8485958">US8485958</a></td><td class="patent-data-table-td patent-date-value">Aug 7, 2012</td><td class="patent-data-table-td patent-date-value">Jul 16, 2013</td><td class="patent-data-table-td ">Kensey Nash Corporation</td><td class="patent-data-table-td ">Systems and methods for separating constituents of biologic liquid mixtures</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8491564">US8491564</a></td><td class="patent-data-table-td patent-date-value">Apr 15, 2009</td><td class="patent-data-table-td patent-date-value">Jul 23, 2013</td><td class="patent-data-table-td ">Cascade Medical Enterprises, Llc</td><td class="patent-data-table-td ">Systems and methods for preparing autologous fibrin glue</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8529956">US8529956</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 17, 2008</td><td class="patent-data-table-td patent-date-value">Sep 10, 2013</td><td class="patent-data-table-td ">Carnell Therapeutics Corporation</td><td class="patent-data-table-td ">Blood-derived plastic bone tissue articles; Young&#39;s Modulus of 0.03 GPa to 50 GPa; article; biological response modifiers hormones, growth factors, cytokines, extracellular matrix molecules; crosslinking agents iridoid derivatives, diimidates, diones; plasticizers phthalate, adipate, plant oils, glycols</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8529958">US8529958</a></td><td class="patent-data-table-td patent-date-value">Jul 6, 2011</td><td class="patent-data-table-td patent-date-value">Sep 10, 2013</td><td class="patent-data-table-td ">Carmell Therapeutics Corporation</td><td class="patent-data-table-td ">Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8529959">US8529959</a></td><td class="patent-data-table-td patent-date-value">Jul 6, 2011</td><td class="patent-data-table-td patent-date-value">Sep 10, 2013</td><td class="patent-data-table-td ">Carmell Therapeutics Corporation</td><td class="patent-data-table-td ">Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8529960">US8529960</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 6, 2011</td><td class="patent-data-table-td patent-date-value">Sep 10, 2013</td><td class="patent-data-table-td ">Carnell Therapeutics Corporation</td><td class="patent-data-table-td ">Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8529961">US8529961</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 6, 2011</td><td class="patent-data-table-td patent-date-value">Sep 10, 2013</td><td class="patent-data-table-td ">Carmell Therapeutics Corporation</td><td class="patent-data-table-td ">Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8551344">US8551344</a></td><td class="patent-data-table-td patent-date-value">Apr 9, 2010</td><td class="patent-data-table-td patent-date-value">Oct 8, 2013</td><td class="patent-data-table-td ">Biomet Manufacturing, Llc</td><td class="patent-data-table-td ">Method and apparatus for producing autologous clotting components</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8556794">US8556794</a></td><td class="patent-data-table-td patent-date-value">Feb 15, 2012</td><td class="patent-data-table-td patent-date-value">Oct 15, 2013</td><td class="patent-data-table-td ">Kensey Nash Corporation</td><td class="patent-data-table-td ">Centrifuge</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8557535">US8557535</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 9, 2009</td><td class="patent-data-table-td patent-date-value">Oct 15, 2013</td><td class="patent-data-table-td ">Incept Llc</td><td class="patent-data-table-td ">Methods for preparation of platelet rich plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8562501">US8562501</a></td><td class="patent-data-table-td patent-date-value">Feb 18, 2013</td><td class="patent-data-table-td patent-date-value">Oct 22, 2013</td><td class="patent-data-table-td ">Kensey Nash Corporation</td><td class="patent-data-table-td ">Methods for separating constituents of biologic liquid mixtures</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8568448">US8568448</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 21, 2012</td><td class="patent-data-table-td patent-date-value">Oct 29, 2013</td><td class="patent-data-table-td ">Closys Corporation</td><td class="patent-data-table-td ">Clotting cascade initiating apparatus and methods of use and methods of closing wounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8617042">US8617042</a></td><td class="patent-data-table-td patent-date-value">Mar 18, 2013</td><td class="patent-data-table-td patent-date-value">Dec 31, 2013</td><td class="patent-data-table-td ">Kensey Nash Corporation</td><td class="patent-data-table-td ">Methods for separating constituents of biologic liquid mixtures</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8617539">US8617539</a></td><td class="patent-data-table-td patent-date-value">Mar 13, 2012</td><td class="patent-data-table-td patent-date-value">Dec 31, 2013</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Method of administration of platelet-rich plasma to treat an acute cardiac dysfunction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8623842">US8623842</a></td><td class="patent-data-table-td patent-date-value">Sep 26, 2007</td><td class="patent-data-table-td patent-date-value">Jan 7, 2014</td><td class="patent-data-table-td ">Hemostasis, Llc</td><td class="patent-data-table-td ">Hemostatic agent and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8652168">US8652168</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 23, 2006</td><td class="patent-data-table-td patent-date-value">Feb 18, 2014</td><td class="patent-data-table-td ">Closys Corporation</td><td class="patent-data-table-td ">Clotting cascade initiating apparatus and methods of use and methods of closing wounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8652169">US8652169</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 28, 2013</td><td class="patent-data-table-td patent-date-value">Feb 18, 2014</td><td class="patent-data-table-td ">Closys Corporation</td><td class="patent-data-table-td ">Clotting cascade initiating apparatus and methods of use and methods of closing wounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8663146">US8663146</a></td><td class="patent-data-table-td patent-date-value">Sep 16, 2011</td><td class="patent-data-table-td patent-date-value">Mar 4, 2014</td><td class="patent-data-table-td ">Biomet Biologics, Llc</td><td class="patent-data-table-td ">Angiogenesis initiation and growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8685258">US8685258</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2009</td><td class="patent-data-table-td patent-date-value">Apr 1, 2014</td><td class="patent-data-table-td ">Fenwal, Inc.</td><td class="patent-data-table-td ">Systems and methods for conveying multiple blood components to a recipient</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8741282">US8741282</a></td><td class="patent-data-table-td patent-date-value">Jun 17, 2008</td><td class="patent-data-table-td patent-date-value">Jun 3, 2014</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Method for treatment of tendinosis with platelet rich plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8747291">US8747291</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 2013</td><td class="patent-data-table-td patent-date-value">Jun 10, 2014</td><td class="patent-data-table-td ">Kensey Nash Corporation</td><td class="patent-data-table-td ">Methods for separating constituents of biologic liquid mixtures</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8753690">US8753690</a></td><td class="patent-data-table-td patent-date-value">Aug 27, 2009</td><td class="patent-data-table-td patent-date-value">Jun 17, 2014</td><td class="patent-data-table-td ">Biomet Biologics, Llc</td><td class="patent-data-table-td ">Methods and compositions for delivering interleukin-1 receptor antagonist</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8758211">US8758211</a></td><td class="patent-data-table-td patent-date-value">Oct 11, 2013</td><td class="patent-data-table-td patent-date-value">Jun 24, 2014</td><td class="patent-data-table-td ">Kensey Nash Corporation</td><td class="patent-data-table-td ">Centrifuge</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8771609">US8771609</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 16, 2007</td><td class="patent-data-table-td patent-date-value">Jul 8, 2014</td><td class="patent-data-table-td ">Siemens Aktiengesellschaft</td><td class="patent-data-table-td ">Module for processing a biological sample, biochip kit, and use of the module</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20080286329">US20080286329</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 17, 2008</td><td class="patent-data-table-td patent-date-value">Nov 20, 2008</td><td class="patent-data-table-td ">Carnegie Mellon University</td><td class="patent-data-table-td ">Blood-derived plastic bone tissue articles; Young&#39;s Modulus of 0.03 GPa to 50 GPa; article; biological response modifiers hormones, growth factors, cytokines, extracellular matrix molecules; crosslinking agents iridoid derivatives, diimidates, diones; plasticizers phthalate, adipate, plant oils, glycols</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20100086529">US20100086529</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 8, 2009</td><td class="patent-data-table-td patent-date-value">Apr 8, 2010</td><td class="patent-data-table-td ">Mohammad Syed F</td><td class="patent-data-table-td ">Methods of making concentrated fibrinogen- and platelet-containing compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20120003193">US20120003193</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 6, 2011</td><td class="patent-data-table-td patent-date-value">Jan 5, 2012</td><td class="patent-data-table-td ">Carnegie Mellon University</td><td class="patent-data-table-td ">Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20120156284">US20120156284</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 28, 2012</td><td class="patent-data-table-td patent-date-value">Jun 21, 2012</td><td class="patent-data-table-td ">Spinal Restoration, Inc.</td><td class="patent-data-table-td ">Enhanced biological autologous tissue adhesive composition and methods of preparation and use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20120177694">US20120177694</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 6, 2011</td><td class="patent-data-table-td patent-date-value">Jul 12, 2012</td><td class="patent-data-table-td ">Carmell Therapeutics Corporation, a Pennsylvania corporation</td><td class="patent-data-table-td ">Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20130211449">US20130211449</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 28, 2013</td><td class="patent-data-table-td patent-date-value">Aug 15, 2013</td><td class="patent-data-table-td ">Closys Corporation</td><td class="patent-data-table-td ">Clotting cascade initiating apparatus and methods of use and methods of closing wounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE102011122227A1?cl=en">DE102011122227A1</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 2011</td><td class="patent-data-table-td patent-date-value">Jun 27, 2013</td><td class="patent-data-table-td ">Medizinische Hochschule Hannover</td><td class="patent-data-table-td ">Verfahren und Vorrichtung zur Herstellung eines bioartifiziellen Gewebekonstrukts</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1057534A1?cl=en">EP1057534A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 10, 2000</td><td class="patent-data-table-td patent-date-value">Dec 6, 2000</td><td class="patent-data-table-td ">Haemonetics Corporation</td><td class="patent-data-table-td ">Centrifugation bowl with filter core</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2258379A1?cl=en">EP2258379A1</a></td><td class="patent-data-table-td patent-date-value">Apr 14, 2003</td><td class="patent-data-table-td patent-date-value">Dec 8, 2010</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Use of platelet rich plasma composition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2628484A1?cl=en">EP2628484A1</a></td><td class="patent-data-table-td patent-date-value">Feb 17, 2012</td><td class="patent-data-table-td patent-date-value">Aug 21, 2013</td><td class="patent-data-table-td ">Quimera Ingenieria Biomedica, S.L.</td><td class="patent-data-table-td ">Platelet-rich plasma compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2666493A2?cl=en">EP2666493A2</a></td><td class="patent-data-table-td patent-date-value">Jan 30, 2006</td><td class="patent-data-table-td patent-date-value">Nov 27, 2013</td><td class="patent-data-table-td ">Hanuman LLC</td><td class="patent-data-table-td ">Platelet rich plasma concentrate apparatus and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2666494A2?cl=en">EP2666494A2</a></td><td class="patent-data-table-td patent-date-value">Jan 30, 2006</td><td class="patent-data-table-td patent-date-value">Nov 27, 2013</td><td class="patent-data-table-td ">Hanuman LLC</td><td class="patent-data-table-td ">Platelet rich plasma concentrate apparatus and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1999020288A1?cl=en">WO1999020288A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 16, 1998</td><td class="patent-data-table-td patent-date-value">Apr 29, 1999</td><td class="patent-data-table-td ">Harvest Technologies Corp</td><td class="patent-data-table-td ">Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1999059670A1?cl=en">WO1999059670A1</a></td><td class="patent-data-table-td patent-date-value">May 20, 1999</td><td class="patent-data-table-td patent-date-value">Nov 25, 1999</td><td class="patent-data-table-td ">Biosurgical Corp</td><td class="patent-data-table-td ">Sealant applicator and method employing impulse clearing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1999062588A1?cl=en">WO1999062588A1</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 1999</td><td class="patent-data-table-td patent-date-value">Dec 9, 1999</td><td class="patent-data-table-td ">Biosurgical Corp</td><td class="patent-data-table-td ">Direct dual filling device for sealing agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1999066797A1?cl=en">WO1999066797A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 13, 1999</td><td class="patent-data-table-td patent-date-value">Dec 29, 1999</td><td class="patent-data-table-td ">Charles E Worden</td><td class="patent-data-table-td ">Enriched platelet wound healant</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1999066923A1?cl=en">WO1999066923A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 21, 1999</td><td class="patent-data-table-td patent-date-value">Dec 29, 1999</td><td class="patent-data-table-td ">Charles E Worden</td><td class="patent-data-table-td ">Application for utility patent for improved enriched platelet wound healant</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2000009181A2?cl=en">WO2000009181A2</a></td><td class="patent-data-table-td patent-date-value">Aug 12, 1999</td><td class="patent-data-table-td patent-date-value">Feb 24, 2000</td><td class="patent-data-table-td ">Biosurgical Corp</td><td class="patent-data-table-td ">Multipurpose fluid applicator and method, with surgical uses</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2000010624A2?cl=en">WO2000010624A2</a></td><td class="patent-data-table-td patent-date-value">Aug 18, 1999</td><td class="patent-data-table-td patent-date-value">Mar 2, 2000</td><td class="patent-data-table-td ">Biosurgical Corp</td><td class="patent-data-table-td ">Sealant applicator tip and application method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2001041650A1?cl=en">WO2001041650A1</a></td><td class="patent-data-table-td patent-date-value">Dec 8, 2000</td><td class="patent-data-table-td patent-date-value">Jun 14, 2001</td><td class="patent-data-table-td ">Baxter Int</td><td class="patent-data-table-td ">Direct dual filling device for sealing agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2001043787A2?cl=en">WO2001043787A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 13, 2000</td><td class="patent-data-table-td patent-date-value">Jun 21, 2001</td><td class="patent-data-table-td ">Maria Cristina Sacchi</td><td class="patent-data-table-td ">A process for preparing an autologous platelet gel and membrane thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2003088843A1?cl=en">WO2003088843A1</a></td><td class="patent-data-table-td patent-date-value">Apr 18, 2003</td><td class="patent-data-table-td patent-date-value">Oct 30, 2003</td><td class="patent-data-table-td ">Baxter Healthcare Sa</td><td class="patent-data-table-td ">Direct dual filing device for sealing agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004058943A2?cl=en">WO2004058943A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 18, 2003</td><td class="patent-data-table-td patent-date-value">Jul 15, 2004</td><td class="patent-data-table-td ">Cobe Cardiovascular Inc</td><td class="patent-data-table-td ">Device and process for the preparation of autologous thrombin serum</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006023502A2?cl=en">WO2006023502A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 17, 2005</td><td class="patent-data-table-td patent-date-value">Mar 2, 2006</td><td class="patent-data-table-td ">Mishra Allan</td><td class="patent-data-table-td ">Particle/cell separation device and compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006086199A1?cl=en">WO2006086199A1</a></td><td class="patent-data-table-td patent-date-value">Jan 30, 2006</td><td class="patent-data-table-td patent-date-value">Aug 17, 2006</td><td class="patent-data-table-td ">Hanuman Llc</td><td class="patent-data-table-td ">Platelet rich plasma concentrate apparatus and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006086200A1?cl=en">WO2006086200A1</a></td><td class="patent-data-table-td patent-date-value">Jan 30, 2006</td><td class="patent-data-table-td patent-date-value">Aug 17, 2006</td><td class="patent-data-table-td ">Hanuman Llc</td><td class="patent-data-table-td ">Plasma concentrator device</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006086201A2?cl=en">WO2006086201A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 30, 2006</td><td class="patent-data-table-td patent-date-value">Aug 17, 2006</td><td class="patent-data-table-td ">Hanuman Llc</td><td class="patent-data-table-td ">Platelet rich plasma concentrate apparatus and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007005820A1?cl=en">WO2007005820A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 30, 2006</td><td class="patent-data-table-td patent-date-value">Jan 11, 2007</td><td class="patent-data-table-td ">Cytomedix Inc</td><td class="patent-data-table-td ">Method for treating wounds with enriched platelet wound healant</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008022218A1?cl=en">WO2008022218A1</a></td><td class="patent-data-table-td patent-date-value">Aug 15, 2007</td><td class="patent-data-table-td patent-date-value">Feb 21, 2008</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Device for cartilage repair</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011028733A1?cl=en">WO2011028733A1</a></td><td class="patent-data-table-td patent-date-value">Aug 31, 2010</td><td class="patent-data-table-td patent-date-value">Mar 10, 2011</td><td class="patent-data-table-td ">Allan Mishra</td><td class="patent-data-table-td ">Compositions and minimally invasive methods for treating cancer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013091865A1?cl=en">WO2013091865A1</a></td><td class="patent-data-table-td patent-date-value">Dec 20, 2012</td><td class="patent-data-table-td patent-date-value">Jun 27, 2013</td><td class="patent-data-table-td ">Medizinische Hochschule Hannover</td><td class="patent-data-table-td ">Method and device for producing a bioartifical tissue construct</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc210/defs210.htm&usg=AFQjCNH7y8SJF1YNVI0_VrDZSnccmFP9xA#C210S782000">210/782</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S530000">424/530</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc210/defs210.htm&usg=AFQjCNH7y8SJF1YNVI0_VrDZSnccmFP9xA#C210S500380">210/500.38</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc494/defs494.htm&usg=AFQjCNEpzBQw8kNWWZbtpAZdnqug-edEfg#C494S033000">494/33</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc494/defs494.htm&usg=AFQjCNEpzBQw8kNWWZbtpAZdnqug-edEfg#C494S031000">494/31</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc494/defs494.htm&usg=AFQjCNEpzBQw8kNWWZbtpAZdnqug-edEfg#C494S036000">494/36</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc422/defs422.htm&usg=AFQjCNHXLT_uXJvUp9ERMJkh6x6moeyOWg#C422S044000">422/44</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc494/defs494.htm&usg=AFQjCNEpzBQw8kNWWZbtpAZdnqug-edEfg#C494S045000">494/45</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61L0024100000">A61L24/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=B04B0005040000">B04B5/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=B01D0063160000">B01D63/16</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0035140000">A61K35/14</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=B01D0067000000">B01D67/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0014745000">C07K14/745</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=B01D0061180000">B01D61/18</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61M0001360000">A61M1/36</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=B01D67/0093">B01D67/0093</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61M1/3696">A61M1/3696</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=B04B5/0442">B04B5/0442</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=B01D63/16">B01D63/16</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=B01D61/18">B01D61/18</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61M1/3693">A61M1/3693</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61L24/106">A61L24/106</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=B04B2005/0478">B04B2005/0478</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=kfFABAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=B01D2323/30">B01D2323/30</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61L24/10F</span>, <span class="nested-value">A61M1/36Z</span>, <span class="nested-value">B04B5/04C</span>, <span class="nested-value">B01D67/00R18</span>, <span class="nested-value">B01D63/16</span>, <span class="nested-value">B01D61/18</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Aug 6, 2013</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 6, 2012</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 1, 2, 4-6, 9, 11-20, 27, 28, 31, 32, 36, 42 AND 43 IS CONFIRMED.CLAIMS 3, 7, 8, 10, 21-26, 29, 30, 33-35, 37-41, 44 AND 45 WERE NOT REEXAMINED.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 11, 2011</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20110811</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 13, 2008</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 13, 2006</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 13, 2006</td><td class="patent-data-table-td ">SULP</td><td class="patent-data-table-td ">Surcharge for late payment</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 11, 2006</td><td class="patent-data-table-td ">PRDP</td><td class="patent-data-table-td ">Patent reinstated due to the acceptance of a late maintenance fee</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20061213</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 15, 2005</td><td class="patent-data-table-td ">FP</td><td class="patent-data-table-td ">Expired due to failure to pay maintenance fee</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20041217</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 17, 2004</td><td class="patent-data-table-td ">REIN</td><td class="patent-data-table-td ">Reinstatement after maintenance fee payment confirmed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 7, 2004</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">May 18, 2000</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 7, 1998</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ETHICON, INC., NEW JERSEY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:PLASMASEAL LLC;REEL/FRAME:008907/0794</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19971205</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 21, 1997</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">PLASMASEAL LLC, CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PLASMASEAL CORPORATION;REEL/FRAME:008467/0352</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19970414</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 21, 1995</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">PLASMASEAL CORPORATION, CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANTANAVICH, RICHARD D.;DORIAN, RANDEL;REEL/FRAME:007343/0358</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19950125</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U0q8Hzbjr4G5aKh0QA5bCXcEamXXg\u0026id=kfFABAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U29MjUH-0JXTj8l2XECwwEl_gl-uw\u0026id=kfFABAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U02kBjGCUh8pvdyPxJM7P0b5BIbig","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Plasma_concentrate_and_tissue_sealant_me.pdf?id=kfFABAABERAJ\u0026output=pdf\u0026sig=ACfU3U0MQG0x0Idp5fl3_Qu5IcnIMCZp3Q"},"sample_url":"http://www.google.com/patents/reader?id=kfFABAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>